



California Regulatory Notice Register

REGISTER 2014, NO. 23-Z

PUBLISHED WEEKLY BY THE OFFICE OF ADMINISTRATIVE LAW

JUNE 6, 2014

PROPOSED ACTION ON REGULATIONS

TITLE 9. MENTAL HEALTH SERVICES OVERSIGHT AND ACCOUNTABILITY COMMISSION
Mental Health Services Act (MHSA) Prevention and Early Intervention — Notice File No. Z2014-0527-07 1049

TITLE 22. OFFICE OF STATEWIDE HEALTH PLANNING AND DEVELOPMENT
Office of Statewide Health Planning and Development (OSHPD) Patient Data Reporting Program Updates — Notice File No. Z2014-0527-02 1056

GENERAL PUBLIC INTEREST

DEPARTMENT OF TOXIC SUBSTANCES CONTROL
Public Comment Period — Proposed Consent Decree 1060

PROPOSITION 65

OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT
Chemical Delisted Effective June 6, 2014 as Known to Cause Reproductive Toxicity: Chlorsulfuron 1061

OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT
Chemicals Known to the State to Cause Cancer or Reproductive Toxicity 1061

OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT
Notice to Change the Basis For Listing for Hexafluoroacetone and Phenylphosphine 1080

SUSPENSION OF ACTION REGARDING UNDERGROUND REGULATIONS

DEPARTMENT OF CORRECTIONS AND REHABILITATION
Computer Expertise From Accessing Institution Computers 1081

(Continued on next page)

Time-Dated Material

SUMMARY OF REGULATORY ACTIONS

Regulations filed with the Secretary of State	1082
Sections Filed, December 25, 2013 to May 28, 2014	1083

The *California Regulatory Notice Register* is an official state publication of the Office of Administrative Law containing notices of proposed regulatory actions by state regulatory agencies to adopt, amend or repeal regulations contained in the California Code of Regulations. The effective period of a notice of proposed regulatory action by a state agency in the *California Regulatory Notice Register* shall not exceed one year [Government Code § 11346.4(b)]. It is suggested, therefore, that issues of the *California Regulatory Notice Register* be retained for a minimum of 18 months.

CALIFORNIA REGULATORY NOTICE REGISTER (USPS 002-931), (ISSN 1041-2654) is published weekly by the Office of Administrative Law, 300 Capitol Mall, Suite 1250, Sacramento, CA 95814-4339. The Register is printed by Barclays, a subsidiary of West, a Thomson Reuters Business, and is offered by subscription for \$205.00 (annual price). To order or make changes to current subscriptions, please call (800) 888-3600. "Periodicals Postage Paid in Saint Paul, MN." **POSTMASTER:** Send address changes to the: CALIFORNIA REGULATORY NOTICE REGISTER, Barclays, a subsidiary of West, a Thomson Reuters Business, P.O. Box 2006, San Francisco, CA 94126. The Register can also be accessed at <http://www.oal.ca.gov>.

**PROPOSED ACTION ON
REGULATIONS**

Information contained in this document is published as received from agencies and is not edited by Thomson Reuters.

**TITLE 9. MENTAL HEALTH SERVICES
OVERSIGHT AND ACCOUNTABILITY
COMMISSION**

**Mental Health Services Act Prevention and Early
Intervention**

NOTICE IS HEREBY GIVEN that the Mental Health Services Oversight and Accountability Commission (Commission) is proposing to take the action described in the Informative Digest after considering all comments, objections, and recommendations regarding the proposed action.

PUBLIC HEARING

The Commission will hold a public hearing starting at 10:00 a.m. on July 24, 2014, at the Mental Health Services Oversight and Accountability Commission located at 1325 J St., Suite 1700 on the 17th Floor in Sacramento, California. The conference room is wheelchair accessible. At the hearing, any person may present statements or arguments orally or in writing relevant to the proposed action described in the Informative Digest. The Commission requests, but does not require, that persons who make oral comments at the hearing also submit a written copy of their testimony at the hearing. The hearing will end when all comments have been received or at 12:00 p.m., whichever comes first.

WRITTEN COMMENT PERIOD

Any interested person, or his or her authorized representative, may submit written comments relevant to the proposed regulatory action to the Commission. Comments may also be submitted by facsimile (FAX) at 916-445-4927 or by e-mail to Lauren.Quintero@mhsoac.ca.gov. The written comment period closes at **5:00 p.m. on July 24, 2014**. The Commission will consider only comments received at the Commission office or at the public hearing, by that time.

Submit comments to:

Lauren Quintero
Mental Health Services Oversight and
Accountability Commission
1325 J St., Suite 1700
Sacramento, CA 95814
(916) 445-8696

AUTHORITY AND REFERENCE

Pursuant to the authority vested by Section 5846 of the Welfare and Institutions Code, the Mental Health Services Oversight and Accountability Commission (Commission) is seeking changes to:

Division 1 of Title 9 of the California Code of Regulations as follows: Adopt Article 2, Sections 3200.245 and 3200.246; Adopt Article 5, Sections 3510.010, 3560, 3560.010, and 3560.020; and Adopt Article 7, Sections 3700, 3705, 3710, 3715, 3720, 3725, 3730, 3735, 3740, 3745, 3750, 3755, and 3755.010. This proposed action implements, interprets, and makes specific Sections 5840, 5846, 5847, 5848, 5892, and 5897, Welfare and Institutions Code and uncodified Sections 2 and 3 of the Mental Health Services Act.

INFORMATIVE DIGEST

On June 26, 2013 Governor Brown signed into law Assembly Bill 82 which went into effect immediately. Assembly Bill 82 gave the Mental Health Services Oversight and Accountability Commission (Commission) the mandate to adopt regulations necessary for the administration of the Prevention and Early Intervention (PEI) component of the Mental Health Services Act (MHSA).

The California voters approved Proposition 63 during the November 2004 General Election. Proposition 63 became effective on January 1, 2005 as the MHSA. The MHSA expands mental health services to children/youth, adults and older adults who are at risk of or have serious mental illness or serious emotional disturbance and whose service needs are not being met through other funding sources. Through imposition of a 1% tax on personal income in excess of \$1 million, the MHSA provides the opportunity to offer increased funding, personnel and resources to support county mental health programs and monitor progress toward statewide goals for children/youth, adults, older adults and families.

Welfare and Institutions Code Section 5847 directs each county mental health program to prepare and submit to the Commission a Three-Year Program and Expenditure Plan (Plan) and annual updates. The Plan is comprised of five components of activities and/or ser-

VICES for which the funding established under the MHSA can be spent. The components are Community Services and Supports for children, transition-age youth, adults and older adults; Capital Facilities and Technological Needs; Workforce Education and Training; Prevention and Early Intervention; and Innovative Programs.

Prior to its elimination on June 30, 2012, the California Department of Mental Health (DMH) had the authority to adopt regulations for all of the MHSA components. Given the scale of each component DMH implemented each component on a sequential and/or phased-in approach. Accordingly, DMH drafted regulations through a concurrent process as the MHSA components were being developed. Regulations for the PEI component had not been adopted prior to June 30, 2012. In July 2012 the Department of Health Care Services (DHCS) was given authority, in consultation with the MHSAOAC, to develop regulations as necessary to implement the MHSA. Then in June 2013, the MHSAOAC was mandated to adopt regulations for the PEI component.

The MHSA-specified purpose for the PEI component is to prevent mental illnesses from becoming severe and disabling (Welfare and Institutions Code Section 5840, subdivision (a)). Section 5840 also requires counties to:

1. Emphasize improving timely access to services for underserved populations (Welfare and Institutions Code Section 5840, subdivision (a)),
2. Conduct outreach to families, employers, primary care health care providers, and others to recognize early signs of potentially severe and disabling mental illnesses (Welfare and Institutions Code Section 5840, subdivision (b)(1)),
3. Create access and linkage to medically necessary care provided by county mental health programs (Welfare and Institutions Code Section 5840, subdivision (b)(2)),
4. Reduce stigma associated with either being diagnosed with a mental illness or seeking mental health services (Welfare and Institutions Code Section 5840, subdivision (b)(3)),
5. Reduce discrimination against people with mental illness (Welfare and Institutions Code Section 5840, subdivision (b)(4)),
6. Include mental health services similar to those provided under other programs effective in preventing mental illnesses from becoming severe (Welfare and Institutions Code Section 5840, subdivision (c)),

7. Include components similar to programs that have been successful in reducing the duration of untreated severe mental illnesses (Welfare and Institutions Code Section 5840, subdivision (c)),
8. Include components similar to programs that have been successful in assisting people in quickly regaining productive lives (Welfare and Institutions Code Section 5840, subdivision (c)),
9. Emphasize strategies to reduce the following negative outcomes that may result from untreated mental illness: suicide, incarcerations, school failure or drop-out, prolonged suffering, unemployment, homelessness, and removal of children from their homes (Welfare and Institutions Code Section 5840, subdivision (d)).

This regulatory proposal would establish, for the first time, regulations for the administration of the PEI component of the MHSA.

This Informative Digest accompanies the proposed regulations to adopt 19 regulations, located in the California Code of Regulations Title 9, Division 1, Chapter 14, Article 2, Definitions, Article 5, Reporting Requirements and Article 7, Prevention and Early Intervention.

POLICY STATEMENT OVERVIEW AND ANTICIPATED BENEFITS OF PROPOSAL

The MHSA goals for the PEI component are the earliest possible identification and initiation of services for individuals with risk or onset of a potentially serious mental illness, as well as various strategies to link individuals to treatment and encourage them to make use of available services. The PEI component adds to public mental health a positive, proactive help-first approach, with the potential to reduce the need for more costly later-onset or crisis-oriented mental health treatments and increased likelihood of positive outcomes. The broad objective of these regulations is to facilitate the transformation of the mental health system from what has traditionally been seen as a fail-first system to a help-first system.

This regulatory proposal benefits the people of California by facilitating uniformity in administration, reporting, and data collection of the PEI component to help ensure that the MHSA is fulfilling its stated purpose and assure California residents that their tax money is being spent effectively.

CONSISTENCY AND COMPATIBILITY WITH EXISTING STATE REGULATIONS

During the process of developing these regulations, the Mental Health Services Oversight and Accountabil-

ity Commission conducted a search of any similar regulations on this topic and found that these are the only regulations dealing in this subject area (Mental Health Services Act Prevention and Early Intervention). Also, the Commission researched the general Mental Health Services Act regulations and met with the Department of Health Care Services to ensure that the Commission's proposed regulations were not duplicate, inconsistent, or incompatible with any other regulations in development by Department of Health Care Services. Therefore the Commission concluded that this regulatory proposal is consistent with existing Mental Health Services Act regulations.

MATERIAL UPON WHICH THE COMMISSION
RELIES IN PROPOSING THE
RULEMAKING ACTION

1. African American Health Institute of San Bernardino County. (2012). Population report of the California Reducing Disparities Project: African American strategic planning workgroup: Reducing mental health disparities in black Californians using community-defined practices: "We ain't crazy."
2. Aguilar-Gaxiola S, et al. (2012). Community-defined solutions for Latino mental health care disparities. California Reducing Disparities Project. Latino Strategic Planning Workgroup Population Report.
3. American Evaluation Association. (2011). "Public Statement on Cultural Competence in Evaluation." Adopted April 2011.
4. American Foundation for Suicide Prevention. (n.d.). Key Research Findings. Retrieved May 15, 2014, from <http://www.afsp.org/understanding-suicide/key-research-findings>.
5. APA Practice Organization. (2007). Reaching Out to Diverse Populations: Opportunities and Challenges. <http://www.apapracticecentral.org>. Retrieved May 15, 2014, from <http://www.apapracticecentral.org/ce/courses/diverse-populations.aspx>.
6. APA Presidential Task Force on Evidence-Based Practice. (2006). Evidence-Based Practice In Psychology. *American Psychologist*, 271-285.
7. Association of Maternal Child Health Programs. (n.d.). Emerging, promising, and best practices definitions.
8. Bentall RP & Fernyhough C. (2008). Social predictors of psychotic experiences: Specificity and psychological mechanisms. *Schizophrenia Bulletin* 34(6). 1012-1020.
9. Bhui K & Bhugra D. (2002). Mental illness in Black and Asian ethnic minorities: pathways to care and outcomes. *Advances in Psychiatric Treatment*, 8, 26-33.
10. California Bridge to Reform Waiver. (2013). California mental health and substance use system needs assessment and service plan: Volume 2, Service Plan, September 30, 2013. California Department of Health Care Services.
11. California Department of Mental Health. (2009). California Strategic Plan on Reducing Mental Health Stigma and Discrimination.
12. California Healthcare Foundation. (2013). Mapping the Gaps: Mental Health in California. Retrieved May 15, 2014, from <http://www.chcf.org/publications/2013/07/data-viz-mental-health>.
13. California State Auditor. (2013). Mental Health Services Act: The State's Oversight Has Provided Little Assurance of the Act's Effectiveness, and Some Counties Can Improve Measurement of Their Program Performance.
14. Center for School Mental Health Analysis and Action. (2006). Cultural competence and school mental health.
15. Cheng R. (2012). California Reducing Disparities Project: Asian-Pacific Islander population report. Pacific Clinics. Prepared for Office of Health Equity, California Department of Public Health.
16. Chow JC, et al. (2003). Racial/ethnic disparities in the use of mental health services in poverty areas. *American Journal of Public Health*, 93(5), 792-797.
17. Cohen AN, et al. (2013). Preferences for family involvement in care among consumers with serious mental illness. *Psychiatric Services*, 64(3), 257-263.
18. Collins RL, et al. (2012). Interventions to reduce mental health stigma and discrimination: A literature review to guide evaluation of California's mental health prevention and early intervention initiative. RAND Corporation.
19. Corrigan PW. (2011). Best practices: Strategic stigma change: Five principles for social marketing campaigns to reduce stigma. *Psychiatric Services*, 62(8), 824-826.

20. Council of National Psychological Associations for the Advancement of Ethnic Minority Interests. (2003). Psychological treatment of ethnic minority populations. Association of Black Psychologists, Washington, DC.
21. Council of State Governments Healthy States Initiative. (2007). School mental health services: Legislator policy brief.
22. Cunningham DL, et al. (2006). Cultural Competence and school mental health. Baltimore, MD: Center for School Mental Health Analysis and Action, Department of Psychiatry, University of Maryland School of Medicine.
23. Department of Health and Human Services. (2011). HHS action plan to reduce racial and ethnic health disparities: A nation free of disparities in health and health care.
24. Drake RE, et al. (2001). Implementing evidence-based practices in routine mental health service settings. *Psychiatric Services* 52(2), 179–182.
25. Falloon RH. (2003). Family interventions for mental disorders: Efficacy and effectiveness. *World Psychiatry* 2(1), 20–28.
26. Family Mental Health Alliance. (2006). Caring together: Families as partners in the mental health and addiction system. Canadian Mental Health Association. Ontario Federation of Community Mental Health and Addiction Programs.
27. Gary FA. (2005). Stigma: Barrier to mental health care among ethnic minorities. *Issues in Mental Health Nursing*, 26, 979–999.
28. Hong JS & Espelage DL. (2012). A review of research on bullying and peer victimization in school: An ecological system analysis. *Aggression and Violent Behavior* (17), 311–322.
29. Housar J and Oman KS. (2011). Evidence-based practice: An implementation guide for organizations. Jones & Bartlett Learning, LLC.
30. IOM (Institute of Medicine). (2001). Crossing the quality chasm: A new health system for the 21st century. Washington, DC: National Academy Press.
31. IOM (Institute of Medicine). (2009). Race, Ethnicity, and Language Data: Standardization for Health Care Quality Improvement. Washington, DC: The National Academies Press.
32. Kataoka S, et al. (2002). Unmet need for mental health care among U.S. children: Variation by ethnicity and insurance status. *American Journal of Psychiatry* 159(9), 1548–1555.
33. King, D. (2011). Pathways to integrated healthcare: Strategies for African American communities and organizations: Consensus statements and recommendations. US Department of Health and Human Services Office of Minority Health.
34. Lieberman R, et al. (2010). Issue brief Using practice-based evidence to complement evidence-based practice in children's behavioral health. Atlanta, GA: ICF Macro, Outcomes Roundtable for Children and Families.
35. Lopez MH. (2014, January 24). In 2014, Latinos will surpass whites as largest racial/ethnic group in California. Pew Research Center. Retrieved May 15, 2014, from <http://www.pewresearch.org/fact-tank/2014/01/24/in-2014-latinos-will-surpass-whites-as-largest-raciaethnic-group-in-california/>.
36. Los Angeles County Department of Mental Health. (2010). Overview of PEI evidence-based practices, promising practices, and community-defined evidence.
37. Mauritz MW, et al. (2013). Prevalence of interpersonal trauma exposure and trauma-related disorders in severe mental illness. *European Journal of Psychotraumatology* 4(10).
38. Mayo Clinic Staff. (n.d.). Mental illness. Risk factors. Retrieved May 15, 2014, from <http://www.mayoclinic.org/diseases-conditions/mental-illness/basics/risk-factors/con-20033813>.
39. McGarry PD, Killackey E, & Yung A. (2008). Early intervention in psychosis: concepts, evidence and future directions. *World Psychiatry* &(3), 148–156.
40. McGuire TG & Miranda J. (2008). New evidence regarding racial and ethnic disparities in mental health: Policy implications. *Health Affairs*, 27(2), 393–403.
41. McHugo GJ, et al. (2007). Fidelity outcomes in the National Implementing Evidence-Based Practices Project. *Psychiatric Services* 58(10), 1279.84.
42. Mental Health Services Oversight and Accountability Commission. (2010). Guidelines for Prevention and Early Intervention (PEI) Statewide Programs.
43. Mental Health Services Oversight and Accountability Commission. (2013). Mental Health Services Oversight and Accountability Commission Evaluation Master Plan.

44. Mikalson P, et al. (2012). First do no harm: Reducing disparities for lesbian, gay, bisexual, transgender; queer and questioning populations in California. The California LGBTQ reducing mental health disparities population report.
45. Moran M. (2009), Investing in early intervention cuts psychosis treatment costs. *Psychiatric News*, 44(21), 18.
46. Muñoz RF et al. (2012). Major depression can be prevented. *American Psychologist* 67(4), 285–295.
47. National Action Alliance: Clinical Care and Intervention Task Force. (2011). Suicide care in systems framework.
48. National Alliance on Mental Illness, (n.d.) An overview of multicultural issues in children’s mental health. NAMI Multicultural Action Center.
49. National Conference Series on Quality Health Care for Culturally Diverse Populations. (2010). Improving access to behavioral health services for ethnic minority populations: barriers, strategies, and solutions.
50. National Institute of Mental Health. (n.d.). Suicide in the U.S.: Statistics and prevention. Retrieved May 15, 2014, from <http://www.nimh.nih.gov/health/publications/suicide-in-the-us-statistics-and-prevention/index.shtml>.
51. Native American Health Center. (2012). Native vision: A focus on improving behavioral health wellness for California Native Americans. California Reducing Disparities Project: Native American Strategic Planning Workgroup Report.
52. O’Connell, et al. (2009). Preventing mental, emotional, and behavioral disorders among young people: Progress and possibilities. National Research Council and Institute of Medicine of the National Academies. Washington, DC: The National Academies Press.
53. Ockene JK, et al. (2007). Integrating evidence-based community and clinical strategies to improve health. *American Journal of Preventive Medicine* 32, 244–242.
54. Office of Minority Health. (2008). Mental Health 101. Retrieved May 15, 2014, from <http://minorityhealth.hhs.gov/templates/browse.aspx?lvl=3&lvlid=81>.
55. Office of the Surgeon General. (2001). Mental Health: Culture, Race, and Ethnicity: A Supplement to Mental Health: A Report of the Surgeon General. Center for Mental Health Services (US); National Institute of Mental Health (US). Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2001 Aug.
56. Primm AB, et al. (2010). The role of public health in addressing racial and ethnic disparities in mental health and mental illness. *Preventing Chronic Disease* 7(1), A20, 1–7.
57. Pumariega et al. (2005). Culturally competent systems of care for children’s mental health: Advances and challenges. *Community Mental Health Journal*, 41, 539–555.
58. Rao D, et al. (2007). Racial and ethnic disparities in mental illness stigma. *Journal of Nervous and Mental Disorders* 195(12): 1020–1023.
59. Rickwood D. (2006). Pathways of recovery: preventing further episodes of mental illness (monograph): Australian Government Department of Health, Commonwealth of Australia, Canberra.
60. Rogers T, et al. (2011). Using DHDS Outcome Indicators for Policy and Systems Change for Program Planning and Evaluation. Atlanta, GA: Centers for Disease Control and Prevention.
61. Saginaw County Community Mental Health Authority. (2005). A guide to evidence-based practices for adults with mental illness.
62. Sanchez K, et al. (2012). Eliminating Disparities through the Integration of Behavioral Health and Primary Care Services for Racial and Ethnic Minorities, Including Populations with Limited English Proficiency: A Review of the Literature. U.S. Department of Health and Human Services, Office of Minority Health and the Hogg Foundation for Mental Health.
63. Saxena S, et al. (2006). Prevention of mental and behavioral disorders: implications for policy and practice. *World Psychiatry* 5(1), 5–14.
64. Scheppers E, et al. (2006). Potential barriers to the use of health services among ethnic minorities: A review. *Family Practice*, 23(3), 325–348.
65. Substance Abuse & Mental Health Services Administration. (2006). Developing a stigma reduction initiative. SAMHSA Pub No SMA-4176. Rockville, MD: Center for Mental Health Services, Substance and Mental Health Services Administration.
66. Substance Abuse & Mental Health Services Administration. (2008). Reasons for not receiving treatment among adults with serious mental illness. The NSDUH Report.

67. Substance Abuse & Mental Health Services Administration. (2010). SAMHSA's Resource Center to Promote Acceptance, Dignity and Social Inclusion Associated with Mental Health (ADS Center). My Story. Retrieved May 15, 2014, from <http://www.promoteacceptance.samhsa.gov/publications/mystory/>.
68. Substance Abuse & Mental Health Services Administration. (2011). Leading change: A plan for SAMHSA's roles and actions 2011–2014. Rockville, MD: SAMHSA.
69. Substance Abuse & Mental Health Services Administration. (n.d.). SAMHSA Criteria. Retrieved May 15, 2014, from <http://captus.samhsa.gov/prevention-practice/defining-evidence-based/samhsa-criteria>.
70. Suicide Prevention Resource Center. (n.d.). Best Practices Registry. Section I: Evidence-Based Programs. Retrieved May 15, 2014, from <http://www.sprc.org/bpr/section-i-evidence-based-programs>.
71. Suicide Prevention Resource Center. (2012). Suicide prevention basics: Introduction to the public health approach. Educational Development Center.
72. Technical Assistance Partnership for Child and Family Mental Health. (2011). Evidence-based practices, practice-based evidence, community-defined evidence: Practices currently being used by systems of care: A snapshot of system of care communities funded 2005–2009.
73. Unutzer J. (2013). The collaborative care model: An approach for integrating physical and mental health care in Medicaid health homes. Center for Medicare and Medicaid Services, Center for Healthcare Strategies and Mathematica Policy Research.
74. US Department of Health and Human Services Center for Disease Control and Prevention. (2008). State Suicide Prevention Planning: A CDC Research Brief.
75. Waddell, et al. (2001). Using family resource centers to support California's young children and their families. UCLA Center for Healthier Children, Families, and Communities.
76. Washington State Institute for Public Policy, (2013). Benefit–Cost Technical Manual: Methods and User Guide. (Document No. 13–10–1201b).
77. Weir K. (2012). The beginnings of mental illness: Autism, schizophrenia and other disorders may have roots in life's earliest stages. *Monitor on Psychology* 43(2), 36.
78. Wilson, et al. (2007). Self–stigma in people with mental illness. *Schizophrenia Bulletin* 33(6), 1312–1318.
79. World Health Organization. (2010). Towards evidence–based suicide prevention programs.
80. World Health Organization. (2012). Risks to mental health: An overview of vulnerabilities and risk factors.

DISCLOSURES REGARDING THE PROPOSED ACTION

The Commission has made the following initial determinations:

Mandate on local agencies and school districts: None.

Proposition 63 created the Mental Health Services Fund, which is directly distributed to the county to fund the MHSAs programs. The county, through a community program planning process, determines, based on available unspent funds, what services to fund with the Mental Health Services Fund.

Costs or savings to any state agency: None.

Cost to any local agency or school district which must be reimbursed in accordance with Government Code sections 17500 through 17630: None.

Other nondiscretionary cost or savings imposed on local agencies: None.

Significant effect on housing costs: None.

Fiscal impact on public agencies including costs or savings to state agencies or costs/savings in federal funding to the state: None.

Significant, statewide adverse economic impact directly affecting business including the ability of California businesses to compete with businesses in other states: None.

Results of the economic impact assessment/analysis:
The Commission concludes that the regulations would not:

- Have a significant, statewide adverse economic impact directly affecting business, including the ability of California businesses to compete with businesses in other states.
- Have a significant impact on the creation of jobs or new businesses or the elimination of jobs or existing businesses or affect the expansion of businesses currently doing business in the State of California.

The Commission has determined that this regulatory proposal will have the following benefits to the health and welfare of California residents, worker safety, and the state's environment:

Benefits of the Proposed Action: There are expected benefits to the health, safety, and welfare of California residents and to the state's quality of life by implement-

ing PEI programs that prevent mental illness from becoming severe and disabling by linking people, including members of underserved populations, earlier in risk or onset and encouraging people to make use of mental health services and supports.

These regulations specify that all county PEI-funded programs must show evidence that they are likely to bring about MHSA-specified outcomes. By ensuring that all PEI-funded activities are clearly linked to specific MHSA purposes, the regulations are likely to benefit the health, safety, and welfare of California residents, including those with unidentified serious mental illness, the larger number with unaddressed risk of or early onset of a potentially serious mental illness, and the still larger number of friends, colleagues, loved ones, and the many service sectors that are adversely affected by unrecognized, unaddressed, and untreated mental illness.

These regulations will require, for the first time, evaluation of all PEI-funded programs and reporting the results. The regulations also introduce uniformity in reporting PEI program data. Today there is no way to determine statewide how PEI funds are being used, much less to understand their impact. The regulations will support counties to better align their efforts with the MHSA; evaluate, communicate, and improve the quality of services through local accountability; and produce useful program and evaluation data that will enable the state to evaluate and communicate the use and usefulness of PEI programs as an essential part of an integrated public mental health system.

Cost impacts on a representative private person or businesses: The Commission is not aware of any cost impacts that a representative private person or business would necessarily incur in reasonable compliance with the proposed action.

Small Business Determination: The proposed regulations would not affect small businesses as these regulations only affect County Mental Health Departments and they already have PEI programs in place.

CONSIDERATION OF ALTERNATIVES

In accordance with Government Code section 11346.5, subdivision (a)(13), the Commission must determine that no reasonable alternative considered by the Commission or that has otherwise been identified and brought to its attention would be more effective in carrying out the purpose for which this action is proposed, would be as effective and less burdensome to affected private persons than the proposed action described in this Notice, or would be more cost-effective to affected private persons and equally effective at implementing the statutory policy or other provision of law.

The Commission invites interested persons to present statements or arguments with respect to alternatives to the proposed regulations at the scheduled hearing or during the written comment period.

CONTACT PERSONS

Inquiries concerning the proposed administrative action may be directed to:

Lauren Quintero
Mental Health Oversight and Accountability
Commission
1325 J St., Suite 1700
Sacramento, CA 95814
(916) 445-8696

The backup contact person for these inquiries is:

Cody Scott
Mental Health Oversight and Accountability
Commission
1325 J St., Suite 1700
Sacramento, CA 95814
(916) 445-8696

Please direct requests for copies of the proposed text (the “express terms”) of the regulations, the Initial Statement of Reasons, or other information upon which the rulemaking is based to Ms. Quintero at the above address.

AVAILABILITY OF INITIAL STATEMENT OF REASONS, TEXT OF PROPOSED REGULATIONS, AND RULEMAKING FILE

The Commission will have the entire rulemaking file available for inspection and copying throughout the rulemaking process at the Commission office at 1325 J St., Suite 1700, Sacramento, CA 95814. As of the date this notice published in the Notice Register, the rulemaking file consists of copies of the exact language of the proposed regulations, the Initial Statement of Reasons, and all of the information upon which the proposal is based.

Following the public comment period the Commission may thereafter adopt the proposals substantially as described below or may modify the proposals if the modifications are sufficiently related to the original text. With the exception of technical or grammatical changes, the full text of any modified proposal will be available for 15 days prior to its adoption from the person designated in this Notice as contact person and will be mailed to those persons who submit written comments related to this proposal, or who provide oral testimony if a public hearing is held, or who have requested notification of any changes to the proposal.

**AVAILABILITY OF THE FINAL STATEMENT
OF REASONS**

Upon its completion, copies of the Final Statement of Reasons may be viewed and downloaded from the Commission's website at www.mhsoac.ca.gov or by contacting Ms. Quintero at the above address.

**AVAILABILITY OF DOCUMENTS ON
THE INTERNET**

Copies of the Notice of Proposed Action, the Initial Statement of Reasons, and the text of the regulations in underline and strikeout can be accessed through the Commission's website at www.mhsoac.ca.gov.

**TITLE 22. OFFICE OF STATEWIDE
HEALTH PLANNING AND
DEVELOPMENT**

**TITLE 22, DIVISION 7, CHAPTER 10, ARTICLE
8: PATIENT DATA REPORTING REQUIREMENTS**

Sections 97215, 97225, 97226, 97227, 97228, 97229, 97231, 97244, 97247, 97248, 97258, 97259, 97260, 97261 and 97264

The Office of Statewide Health Planning and Development ("the Office") proposes to adopt the proposed regulations described below after considering all comments, objections, and recommendations regarding the proposed action.

The Office proposes to update the disposition codes used for the Hospital Discharge Data, Emergency Care Data, and Ambulatory Surgery Data reporting programs to follow national standards, and to require a valid "Principal Diagnosis" code for each record. The Office also proposes to eliminate outdated language related to reporting patient data by diskette or compact disk. Finally, the Office proposes to amend regulations to delay the implementation date of ICD-10 to October 1, 2015 in response to recent federal legislative changes. No unrelated changes are proposed.

I. PUBLIC HEARING

The Office has not scheduled a public hearing on this proposed action. However, the Office will hold a hearing if it receives a written request for a public hearing from any interested person, or his or her authorized representative, no later than 15 days before the close of the written comment period.

**II. WRITTEN PUBLIC COMMENT PERIOD
AND CONTACT PERSON**

Any interested person, or his or her authorized representative, may submit written comments relevant to the proposed regulatory action. All comments must be received by the Office by 5:00 p.m. on July 21, 2014.

Inquiries and written comments regarding the proposed action should be addressed to the primary contact person named below. Comments delivered by e-mail are preferred. Comments may also be faxed, hand delivered, or mailed to:

Peter Won, Associate Governmental Program
Analyst
Healthcare Information Division
Office of Statewide Health Planning and
Development
400 R Street, Room 250
Sacramento, CA 95811-6213
Fax: (916) 322-9718
Tel: (916) 326-3800
E-mail: Peter.Won@oshpd.ca.gov

Inquiries and comments may also be directed to the backup contact person:

Ronald Spingarn, Deputy Director
Healthcare Information Division
Office of Statewide Health Planning and
Development
400 A Street, Room 250
Sacramento, CA 95811-6213
Fax: (916) 322-9718
Tel: (916) 326-3801
E-mail: Ron.Spingarn@oshpd.ca.gov

Comments should include the author's name, U.S. Postal Service address, and e-mail address, if applicable, for the Office to provide copies of any notices for proposed changes to the regulation text on which additional comments may be solicited.

Following the public comment period the Office may adopt the proposal substantially as described below or, after considering all comments, recommendations, and objections regarding the proposed updates, may modify the proposal and offer a second public comment period. With the exception of technical grammatical changes, the full text of any modified proposal will be available on the Office's website for at least 15 days prior to its adoption. If there is a modified proposal it may also be available by contacting the contact person designated in this notice.

III. AUTHORITY AND REFERENCE

Authority: California Health and Safety Code, Sections 128755 and 128810.

Reference: California Health and Safety Code, Sections 128735, 128736, and 128737.

IV. INFORMATIVE DIGEST/POLICY STATEMENT OVERVIEW

a. Summary of Existing Laws

Hospitals and freestanding ambulatory surgery clinics licensed by the California Department of Public Health are required by law to file certain patient-level information with the Office at specified intervals. Health and Safety Code subsection 128735(g) requires that each California hospital file a Hospital Discharge Abstract Data Record for each patient discharged from the hospital. These records are sometimes referred to as the inpatient data. In addition, these hospitals must file an Emergency Care Data Record for each encounter in a hospital emergency department (Health and Safety Code §128736) and these hospitals and licensed freestanding ambulatory surgery clinics must file an Ambulatory Surgery Data Record for each patient encounter during which at least one ambulatory surgery procedure is performed (Health and Safety Code §128737). These two types of records are sometimes referred to as outpatient data.

The Health and Safety Code require a uniform set of data elements for each record type. These data reporting requirements have been implemented in Article 8 (Patient Data Reporting Requirements) of Chapter 10 of Division 7 of Title 22.

In addition, under Health and Safety Code subsections 128735(f), 128736(d), and 128737(d), “Data reporting requirements established by the office shall be consistent with national standards, as applicable.”

All three types of patient data records include diagnosis and procedure information which is reported using standard code systems. A recent federal law change has delayed the federal adoption of new coding systems (known as ICD-10) from October 1, 2014 to at least October 1, 2015; current program regulations include the 2014 date and now must be amended to address the delay.

b. Effect of the Proposed Rulemaking

The Office is proposing regulatory changes to the patient data reporting requirements effective January 1, 2015, that would: 1) update both inpatient and outpatient disposition codes to conform to national standards; the Format and File Specifications documents which are incorporated by reference would also be updated to reflect changes to the disposition codes, 2) require a valid “Principal Diagnosis” code on each record submitted to the Office, 3) eliminate language related to reporting by diskette or compact disk, and 4) amend the ICD-10 implementation date; the Format and File Specifica-

tions must also be updated to reflect this change. The new versions of the Format and File Specifications that will be incorporated by reference to reflect these changes are titled: Format and File Specifications for MIRCAl Online Transmission: Inpatient Data as revised on April 14, 2014, Format and File Specifications for MIRCAl Online Transmission: Emergency Care Data as revised on April 14, 2014, and Format and File Specifications for MIRCAl Online Transmission: Ambulatory Surgery Data as revised on April 14, 2014.

c. Policy Statement Overview and Benefits of Proposed Regulations

1. Updating the “Disposition of patient” codes

Under Health and Safety Code subsections 128735(f), 128736(d), and 128737(d), “Data reporting requirements established by the office shall be consistent with national standards, as applicable.”

The first regulatory change proposed, aligning the inpatient and outpatient disposition codes to conform to national standards, is being proposed to meet the statutory requirement of following national standards, as applicable. In addition, the benefit of adopting the new definition of the “disposition of patient” data elements is threefold. First, it allows the Office to move to the current national standard definition for all three data programs, thus meeting the statutory goal stated above. Second, for the reporting facilities, reporting data under a standard definition that they already apply in their business is generally easier and more efficient than reporting using categories developed by and unique to the Office. Third, the data collected will be more detailed, more reflective of the industry, and more comparable to other existing data and thus of higher value to data users. This will allow the Office to better serve its purpose listed above by providing more valuable and useful data.

2. Requiring a valid “Principal Diagnosis” code on each record

The purpose of the data collection program is to collect accurate, reliable, useful, and timely information for use in making informed decisions in the health care marketplace, assessing the effectiveness of California’s health care systems and supporting statewide health policy development and evaluation.

The second regulatory change proposed, requiring a valid “Principal Diagnosis” code on each record submitted to the Office, would meet the Office’s purpose of collecting accurate and useful information.

“Principal Diagnosis” is one of the most used and valuable data elements that the Office collects and it is used to research multiple medical conditions in California. Whenever there is not a valid “Principal Diagnosis” code researchers may get an incomplete picture of those affected by a particular condition, which reduces the

quality of research results. Requiring a valid “Principal Diagnosis” code will not only make the Office’s data more complete, but also more useful. In addition, there is no reason for a record not to include a valid “Principal Diagnosis” code since diagnosis codes include values for “unknown” and therefore if there are cases where a facility does not know the “Principal Diagnosis” code for a patient, a valid code can still be reported.

3. Amending 22 CCR § 97244 to eliminate language related to reporting by “diskette or compact disk”

The patient data programs require occasional updates to support administrative efficiency, both for the Office and for the reporting entities.

The benefit of deleting language related to reporting by diskette or compact disk under 22 CCR § 97244 is administrative. This language is outdated and no longer in use. Previously, its purpose was to ease hospitals and freestanding ambulatory surgery clinics through the transition to submitting data electronically. This proposed change will simplify the regulations text without altering any rights or responsibilities of the reporting facilities and it will benefit the Office by streamlining the process of keeping the regulations updated. Because the language proposed for deletion includes cross-references to the Format and File Specifications documents, each time those documents (incorporated by reference in 22 CCR § 97215) are updated, 22 CCR § 97244 also has to be amended. Deleting the language will eliminate that additional cumbersome process.

4. Amending the ICD–10 start date

Use of ICD coding for diagnoses and inpatient procedures is consistent with coding requirements of the Health Insurance and Portability and Accountability Act of 1996 (known as HIPAA). All California hospitals and licensed freestanding ambulatory surgery clinics are HIPAA covered entities. Therefore, the facilities are using the same coding system to report diagnosis and inpatient procedure data to OSHPD as they use (pursuant to federal mandate) for business purposes. The current system used is known as ICD–9.

Until recently, HIPAA required covered entities to convert from using ICD–9 to ICD–10 as of October 1, 2014. The Office promulgated regulations to be consistent with that transition date. However, newly enacted federal legislation delayed the implementation date of the HIPAA–mandated transition to at least October 1, 2015.

This regulatory action would postpone the implementation date of ICD–10 for reporting purposes to October 1, 2015 in order to be consistent with the federal delay.

d. Determination of Inconsistency/Incompatibility with Existing State Regulations

As required by Government Code subsection 11346.5(a)(3)(D), the Office evaluated the language contained in the proposed amendments. The Office has determined that these proposed regulations are not inconsistent with or incompatible with existing state regulations. These regulations make minor modifications to existing programs.

V. DISCLOSURES REGARDING THE PROPOSED ACTION

OSHPD has made the following initial determinations:

- a. Mandate on local agencies and school districts: None.
- b. Cost or savings to any state agency: None.
- c. Cost to any local agency or school district which must be reimbursed in accordance with Government Code sections 17500 through 17630: None.
- d. Other nondiscretionary cost or savings imposed on local agencies: None.
- e. Cost or savings in federal funding to the state: None.
- f. Cost impact on a representative business/small business: The Office anticipates a minor one–time cost to hospitals estimated at \$7,875 to reprogram data collection software that was developed for the Office–specific nonstandard disposition codes. Among these hospitals one would be classified as a small business, which we believe will have similar costs when compared to other hospitals. Because outpatient data has always been reported using the national standard, this minor update to incorporate the revised national standard will not require reprogramming. Therefore, the Office anticipates no costs to outpatient facilities.
- g. Statewide adverse economic impact directly affecting businesses and individuals: The Office has initially determined that the regulations will not have a significant statewide adverse economic impact directly affecting businesses, including the ability of California businesses to compete with businesses in other states.
- h. Significant effect on housing costs: None.

VI. STATEMENT OF THE RESULTS OF THE ECONOMIC IMPACT ANALYSIS (EIA)

The requirement of a valid “Principal Diagnosis” code and removing the obsolete text regarding diskette

and compact disk submissions will have no economic impact. Updating disposition of patient codes for inpatient data may result in minor one-time costs to hospitals to reprogram data-collection software that was developed for the Office-specific nonstandard disposition codes. Updating the disposition of patient codes for outpatient data should have no economic impact. Because outpatient data has always been reported using the national standard, this minor update to incorporate the revised national standard will not require reprogramming. There will also be no cost to facilities to continue reporting ICD-9 data to the Office; allowing facilities to report using the coding system they are required to use for business purposes avoids imposing extra costs.

Therefore, the Office concludes that:

- (1) this regulatory action will not create jobs within the state;
- (2) this regulatory action will not eliminate jobs within the state;
- (3) this regulatory action will not create new businesses;
- (4) this regulatory action will not eliminate existing businesses;
- (5) this regulatory action will not affect the expansion of businesses currently doing business in the state; and
- (6) the benefit to the public is that more accurate and useful data will be available. Such data are used for understanding California's healthcare environment, which may benefit the health and welfare of California residents.

VII. REASONABLE ALTERNATIVES

In accordance with Government Code section 11346.5, subdivision (a)(13), the Office must determine that no reasonable alternative it considered or that has otherwise been identified and brought to the attention of the agency would be more effective in carrying out the purpose for which the action is proposed or would be as effective and less burdensome to affected private persons than the proposed action or would be more cost-effective to affected private persons and equally effective in implementing the statutory policy or other provision of law.

VIII. AVAILABILITY OF EXPRESS TERMS, INITIAL STATEMENT OF REASONS, AND INFORMATION UPON WHICH PROPOSED RULEMAKING IS BASED

a. Availability of Express Terms

The text of the proposed regulations will be available on the Office's website <http://www.oshpd.ca.gov/LawsRegs/NewRegulations.html>. A hardcopy will be available from the Office upon request. The text of the proposed regulations will also be available for review from the designated contact person.

b. Availability of Initial Statement of Reasons

The text of the Initial Statement of Reasons will be available on the Office's website <http://www.oshpd.ca.gov/LawsRegs/NewRegulations.html>. A hardcopy will be available from the Office upon request. The initial statement of reasons will also be available for review from the designated contact person.

c. Availability of Information upon which Proposed Rulemaking is based

In developing these regulations, the Office conducted a survey of affected hospitals and freestanding ambulatory surgery clinics. Facilities were asked whether they would support the proposed changes, and if they anticipated any fiscal impact to their facilities. Copies of the survey and survey results will be made available upon request.

IX. AVAILABILITY OF SUBSTANTIAL CHANGES TO ORIGINAL PROPOSAL

The text of any modified regulation, unless the modification is non-substantial or solely grammatical in nature, will be made available on the Office's website <http://www.oshpd.ca.gov/LawsRegs/NewRegulations.html> at least 15 days prior to the date that the Office adopts the regulation. The changes will be underlined where text is added and struck through where text is deleted. The Office may adopt, amend, or repeal the foregoing proposal substantially as set forth without further notice.

X. AVAILABILITY OF FINAL STATEMENT OF REASONS

The Final Statement of Reasons, including all of the comments and responses, will be available, after its

completion, through our website at <http://www.oshpd.ca.gov/LawsRegs/NewRegulations.html>. The Final Statement of Reasons will also be available for review from the designated contact person.

XI. AVAILABILITY OF DOCUMENTS ON THE INTERNET

Copies of the Notice of Proposed Action, the Initial Statement of Reasons, and the text of the regulations in underline and strikethrough can be accessed through our website at <http://www.oshpd.ca.gov/LawsRegs/NewRegulations.html>.

GENERAL PUBLIC INTEREST

DEPARTMENT OF TOXIC SUBSTANCES CONTROL

**NOTICE OF PUBLIC COMMENT PERIOD
PROPOSED CONSENT DECREE
STANDARD NICKEL CHROMIUM PLATING
COMPANY
Los Angeles, California
PUBLIC COMMENT PERIOD:
June 6, 2014 to July 7, 2014**

WHAT IS BEING PROPOSED? — The Department of Toxic Substances Control (DTSC) invites the public to review and comment on a proposed Consent Decree with Dick Dulgarian, regarding the Standard Nickel Chromium property located at 811, 817/819, 825, and 826 East 62nd Street, Los Angeles, California. Under the proposed Consent Decree, the Estate of Dick Dulgarian will pay approximately \$250,000 to reimburse DTSC for a portion of its remediation and oversight costs, subject to certain conditions and reservations.

HOW CAN I GET INVOLVED? — DTSC will consider public comments on the Consent Decree that are postmarked or received by July 7, 2014. DTSC may decline to finalize the Consent Decree if such com-

ments disclose facts or considerations that indicate the proposed Consent Decree is inappropriate, improper or inadequate. Comments should be addressed to:

Tedd Yargeau
Cleanup Program — GDD Decree
Department of Toxic Substances Control
9211 Oakdale Avenue
Chatsworth, CA 91311
tedd.yargeau@dtsc.ca.gov
*Please include the phrase
“Dick Dulgarian CD Comments”
in the subject line of your letter or e-mail.*

WHERE DO I GET INFORMATION? The proposed Consent Decree and other documents related to the facility are available at the following location:

DTSC Regional Records Office
File Room (By appointment only)
9211 Oakdale Avenue
Chatsworth, CA 91311
Phone: Glenn Castillo (818) 717-6522

Copies of these documents, key technical reports, and other site-related information are also available online at DTSC’s website: www.envirostor.dtsc.ca.gov/public/profile_report.asp?global_id=71003183.

A copy of the 18 page proposed Consent Decree may also be obtained by mail from the DTSC by written request sent to:

Tedd Yargeau — GDD Decree, Cleanup Program,
9211 Oakdale Ave, Chatsworth, CA 91311, fax (818)
717-6557 or e-mail tedd.yargeau@dtsc.ca.gov

FOR ADDITIONAL INFORMATION: If you have any questions or wish to discuss the Consent Decree please contact:

For The Project:
Tedd Yargeau
DTSC Project Manager
(818) 212-5340
tedd.yargeau@dtsc.ca.gov

For Public Participation:
Zenzi A Poindexter
Public Participation Specialist
(866) 495-5651 3, 3
zenzi.poindexter@dtsc.ca.gov

PROPOSITION 65

**OFFICE OF ENVIRONMENTAL
HEALTH HAZARD ASSESSMENT**

**SAFE DRINKING WATER AND TOXIC
ENFORCEMENT ACT OF 1986
(PROPOSITION 65)**

**CHEMICAL DELISTED EFFECTIVE JUNE 6,
2014**

**AS KNOWN TO THE STATE OF CALIFORNIA
TO CAUSE REPRODUCTIVE TOXICITY:
CHLORSULFURON**

JUNE 6, 2014

Effective June 6, 2014, the Office of Environmental Health Hazard Assessment (OEHHA) is removing chlorsulfuron from the list of chemicals known to the State of California to cause reproductive toxicity for purposes of Proposition 65¹.

Chlorsulfuron was added to the list on May 14, 1999, based on its formal identification by the U.S. Environmental Protection Agency (U.S. EPA), an authoritative body², as causing reproductive toxicity. On November 18, 2013, U.S. EPA concluded that there is no compelling evidence of reproductive toxicity for chlorsulfuron³. Following receipt of a petition from DuPont Crop Protection, OEHHA reviewed the basis for listing the chemical. Subsequently, pursuant to regulatory requirements⁴, OEHHA referred chlorsulfuron to the Devel-

¹ The Safe Drinking Water and Toxic Enforcement Act of 1986, Health and Safety Code section 25249.5 et seq.

² See Health and Safety Code, section 25249.8(b) and Title 27, Cal. Code of Regs., section 25306(l).

³ Federal Register (<https://www.federalregister.gov/articles/2013/12/09/2013-28365/chlorsulfuron-community-right-to-know-toxic-chemical-release-reporting#h-7>).

⁴ Title 27, Cal. Code of Regs. section 25306(j)(2).

opmental and Reproductive Toxicant Identification Committee (DARTIC) for reconsideration. In its official capacity as the "state's qualified experts", the DARTIC at a public meeting on May 21, 2014 determined that the chemical has not been clearly shown through scientifically valid testing according to generally accepted principles to cause reproductive toxicity. Consequently, the chemical is being removed from the list.

A complete, updated chemical list is published in this issue of the California Regulatory Notice Register and is available on the OEHHA website at <http://www.oehha.ca.gov/prop65/prop65list/Newlist.html>.

**OFFICE OF ENVIRONMENTAL
HEALTH HAZARD ASSESSMENT**

**SAFE DRINKING WATER AND TOXIC
ENFORCEMENT ACT OF 1986**

**CHEMICALS KNOWN TO THE STATE
TO CAUSE CANCER OR
REPRODUCTIVE TOXICITY
JUNE 6, 2014**

The Safe Drinking Water and Toxic Enforcement Act of 1986 requires that the Governor revise and republish at least once per year the list of chemicals known to the State to cause cancer or reproductive toxicity. The identification number indicated in the following list is the Chemical Abstracts Service (CAS) Registry Number. No CAS number is given when several substances are presented as a single listing. The date refers to the initial appearance of the chemical on the list. For easy reference, chemicals which are shown underlined are newly added. Chemicals which are shown with a strikethrough were placed on the list with the date noted, and have subsequently been removed.

CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER

<u>Chemical</u>	<u>CAS Number</u>	<u>Date</u>
A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole)	26148-68-5	January 1, 1990
Acetaldehyde	75-07-0	April 1, 1988
Acetamide	60-35-5	January 1, 1990
Acetochlor	34256-82-1	January 1, 1989
2-Acetylaminofluorene	53-96-3	July 1, 1987
Acifluorfen sodium	62476-59-9	January 1, 1990
Acrylamide	79-06-1	January 1, 1990
Acrylonitrile	107-13-1	July 1, 1987
Actinomycin D	50-76-0	October 1, 1989

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

<i>Chemical</i>	<i>CAS Number</i>	<i>Date</i>
AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide	3688-53-7	July 1, 1987
Aflatoxins	—	January 1, 1988
Alachlor	15972-60-8	January 1, 1989
Alcoholic beverages, when associated with alcohol abuse	—	July 1, 1988
Aldrin	309-00-2	July 1, 1988
Allyl chloride <u>Delisted October 29, 1999</u>	107-05-1	January 1, 1990
2-Aminoanthraquinone	117-79-3	October 1, 1989
<i>p</i> -Aminoazobenzene	60-09-3	January 1, 1990
<i>ortho</i> -Aminoazotoluene	97-56-3	July 1, 1987
4-Aminobiphenyl (4-aminodiphenyl)	92-67-1	February 27, 1987
1-Amino-2,4-dibromoanthraquinone	81-49-2	August 26, 1997
3-Amino-9-ethylcarbazole hydrochloride	6109-97-3	July 1, 1989
2-Aminofluorene	153-78-6	January 29, 1999
1-Amino-2-methylantraquinone	82-28-0	October 1, 1989
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole	712-68-5	July 1, 1987
4-Amino-2-nitrophenol	119-34-6	January 29, 1999
Amitrole	61-82-5	July 1, 1987
Amsacrine	51264-14-3	August 7, 2009
Analgesic mixtures containing phenacetin	—	February 27, 1987
Androstenedione	63-05-8	May 3, 2011
Aniline	62-53-3	January 1, 1990
Aniline hydrochloride	142-04-1	May 15, 1998
<i>ortho</i> -Anisidine	90-04-0	July 1, 1987
<i>ortho</i> -Anisidine hydrochloride	134-29-2	July 1, 1987
Antimony oxide (Antimony trioxide)	1309-64-4	October 1, 1990
Anthraquinone	84-65-1	September 28, 2007
Aramite	140-57-8	July 1, 1987
Areca nut	—	February 3, 2006
Aristolochic acids	—	July 9, 2004
Arsenic (inorganic arsenic compounds)	—	February 27, 1987
Asbestos	1332-21-4	February 27, 1987
Auramine	492-80-8	July 1, 1987
Azacitidine	320-67-2	January 1, 1992
Azaserine	115-02-6	July 1, 1987
Azathioprine	446-86-6	February 27, 1987
Azobenzene	103-33-3	January 1, 1990
Benthiavalicarb-isopropyl	177406-68-7	July 1, 2008
Benz[a]anthracene	56-55-3	July 1, 1987
Benzene	71-43-2	February 27, 1987
Benzidine [and its salts]	92-87-5	February 27, 1987
Benzidine-based dyes	—	October 1, 1992
Benzo[b]fluoranthene	205-99-2	July 1, 1987
zo[j]fluoranthene	205-82-3	July 1, 1987
Benzo[k]fluoranthene	207-08-9	July 1, 1987
Benzofuran	271-89-6	October 1, 1990
Benzophenone	119-61-9	June 22, 2012
Benzo[a]pyrene	50-32-8	July 1, 1987
Benzotrithloride	98-07-7	July 1, 1987
Benzyl chloride	100-44-7	January 1, 1990
Benzyl violet 4B	1694-09-3	July 1, 1987
Beryllium and beryllium compounds	—	October 1, 1987
Betel quid with tobacco	—	January 1, 1990
Betel quid without tobacco	—	February 3, 2006

<i>Chemical</i>	<i>CASNumber</i>	<i>Date</i>
2,2-Bis(bromomethyl)-1,3-propanediol	3296-90-0	May 1, 1996
Bis(2-chloroethyl)ether	111-44-4	April 1, 1988
N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornapazine)	494-03-1	February 27, 1987
Bischloroethyl nitrosourea (BCNU) (Carmustine)	154-93-8	July 1, 1987
Bis(chloromethyl)ether	542-88-1	February 27, 1987
Bis(2-chloro-1-methylethyl) ether, technical grade	—	October 29, 1999
Bitumens, extracts of steam-refined and air refined	—	January 1, 1990
Bracken fern	—	January 1, 1990
Bromate	15541-45-4	May 31, 2002
Bromochloroacetic acid	5589-96-8	April 6, 2010
Bromodichloromethane	75-27-4	January 1, 1990
Bromoethane	74-96-4	December 22, 2000
Bromoform	75-25-2	April 1, 1991
1,3-Butadiene	106-99-0	April 1, 1988
1,4-Butanediol dimethanesulfonate (Busulfan)	55-98-1	February 27, 1987
Butylated hydroxyanisole	25013-16-5	January 1, 1990
beta-Butyrolactone	3068-88-0	July 1, 1987
Cacodylic acid	75-60-5	May 1, 1996
Cadmium and cadmium compounds	—	October 1, 1987
Caffeic acid	331-39-5	October 1, 1994
Captafol	2425-06-1	October 1, 1988
Captan	133-06-2	January 1, 1990
Carbaryl	63-25-2	February 5, 2010
Carbazole	86-74-8	May 1, 1996
<i>Chemical</i>	<i>CASNumber</i>	<i>Date</i>
Carbon black (airborne, unbound particles of respirable size)	1333-86-4	February 21, 2003
Carbon tetrachloride	56-23-5	October 1, 1987
Carbon-black extracts	—	January 1, 1990
N-Carboxymethyl-N-nitrosourea	60391-92-6	January 25, 2002
Catechol	120-80-9	July 15, 2003
Ceramic fibers (airborne particles of respirable size)	—	July 1, 1990
Certain combined chemotherapy for lymphomas	—	February 27, 1987
Chloral	75-87-6	September 13, 2013
Chloral hydrate	302-17-0	September 13, 2013
Chlorambucil	305-03-3	February 27, 1987
Chloramphenicol <u>Delisted January 4, 2013</u>	56-75-7	October 1, 1989
Chloramphenicol sodium succinate	982-57-0	September 27, 2013
Chlordane	57-74-9	July 1, 1988
Chlordecone (Kepone)	143-50-0	January 1, 1988
Chlordimeform	6164-98-3	January 1, 1989
Chlorendic acid	115-28-6	July 1, 1989
Chlorinated paraffins (Average chain length, C12; approximately 60 percent chlorine by weight)	108171-26-2	July 1, 1989
p-Chloroaniline	106-47-8	October 1, 1994
p-Chloroaniline hydrochloride	20265-96-7	May 15, 1998
Chlorodibromomethane <u>Delisted October 29, 1999</u>	124-48-1	January 1, 1990
Chloroethane (Ethyl chloride)	75-00-3	July 1, 1990
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	13010-47-4	January 1, 1988
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU)	13909-09-6	October 1, 1988
Chloroform	67-66-3	October 1, 1987
Chloromethyl methyl ether (technical grade)	107-30-2	February 27, 1987

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

<u>Chemical</u>	<u>CAS Number</u>	<u>Date</u>
3-Chloro-2-methylpropene	563-47-3	July 1, 1989
1-Chloro-4-nitrobenzene	100-00-5	October 29, 1999
4-Chloro-ortho-phenylenediamine	95-83-0	January 1, 1988
<i>p</i> -Chloro- <i>o</i> -toluidine	95-69-2	January 1, 1990
<i>p</i> -Chloro- <i>o</i> -toluidine, strong acid salts of	—	May 15, 1998
5-Chloro- <i>o</i> -toluidine and its strong acid salts	—	October 24, 1997
Chloroprene	126-99-8	June 2, 2000
Chlorothalonil	1897-45-6	January 1, 1989
Chlorotrianisene	569-57-3	September 1, 1996
Chlorozotocin	54749-90-5	January 1, 1992
Chromium (hexavalent compounds)	—	February 27, 1987
Chrysene	218-01-9	January 1, 1990
C.I. Acid Red 114	6459-94-5	July 1, 1992
C.I. Basic Red 9 monohydrochloride	569-61-9	July 1, 1989
C.I. Direct Blue 15	2429-74-5	August 26, 1997
C.I. Direct Blue 218	28407-37-6	August 26, 1997
C.I. Disperse Yellow 3	2832-40-8	February 8, 2013
C.I. Solvent Yellow 14	842-07-9	May 15, 1998
Ciclosporin (Cyclosporin A; Cyclosporine)	59865-13-3	January 1, 1992
	79217-60-0	
Cidofovir	113852-37-2	January 29, 1999
Cinnamyl anthranilate	87-29-6	July 1, 1989
Cisplatin	15663-27-1	October 1, 1988
Citrus Red No. 2	6358-53-8	October 1, 1989
Clofibrate	637-07-0	September 1, 1996
Clomiphene citrate	50-41-9	May 24, 2013
Cobalt metal powder	7440-48-4	July 1, 1992
Cobalt [II] oxide	1307-96-6	July 1, 1992
Cobalt sulfate	10124-43-3	May 20, 2005
Cobalt sulfate heptahydrate	10026-24-1	June 2, 2000
Coconut oil diethanolamine condensate (cocamide diethanolamine)	68603-42-9	June 22, 2012
Coke oven emissions	—	February 27, 1987
Conjugated estrogens	—	February 27, 1987
Creosotes	—	October 1, 1988
<i>para</i> -Cresidine	120-71-8	January 1, 1988
Cumene	98-82-8	April 6, 2010
Cupferron	135-20-6	January 1, 1988
Cycasin	14901-08-7	January 1, 1988
Cyclopenta[<i>cd</i>]pyrene	27208-37-3	April 29, 2011
Cyclophosphamide (anhydrous)	50-18-0	February 27, 1987
Cyclophosphamide (hydrated)	6055-19-2	February 27, 1987
Cytembena	21739-91-3	May 15, 1998
D&C Orange No. 17	3468-63-1	July 1, 1990
D&C Red No. 8	2092-56-0	October 1, 1990
D&C Red No. 9	5160-02-1	July 1, 1990
D&C Red No. 19	81-88-9	July 1, 1990
Dacarbazine	4342-03-4	January 1, 1988
Daminozide	1596-84-5	January 1, 1990
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	117-10-2	January 1, 1992
Daunomycin	20830-81-3	January 1, 1988
DDD (Dichlorodiphenyldichloroethane)	72-54-8	January 1, 1989
DDE (Dichlorodiphenyldichloroethylene)	72-55-9	January 1, 1989
DDT (Dichlorodiphenyltrichloroethane)	50-29-3	October 1, 1987

<i>Chemical</i>	<i>CASNumber</i>	<i>Date</i>
DDVP (Dichlorvos)	62-73-7	January 1, 1989
N,N' -Diacetylbenzidine	613-35-4	October 1, 1989
2,4-Diaminoanisole	615-05-4	October 1, 1990
2,4-Diaminoanisole sulfate	39156-41-7	January 1, 1988
4,4' -Diaminodiphenyl ether (4,4' -Oxydianiline)	101-80-4	January 1, 1988
2,4-Diaminotoluene	95-80-7	January 1, 1988
Diaminotoluene (mixed)	—	January 1, 1990
Diazoaminobenzene	136-35-6	May 20, 2005
Dibenz[a,h]acridine	226-36-8	January 1, 1988
Dibenz[a,j]acridine	224-42-0	January 1, 1988
Dibenz[a,h]anthracene	53-70-3	January 1, 1988
7H-Dibenzo[c,g]carbazole	194-59-2	January 1, 1988
Dibenzo[a,e]pyrene	192-65-4	January 1, 1988
Dibenzo[a,h]pyrene	189-64-0	January 1, 1988
Dibenzo[a,i]pyrene	189-55-9	January 1, 1988
Dibenzo[a,l]pyrene	191-30-0	January 1, 1988
Dibromoacetic acid	631-64-1	June 17, 2008
Dibromoacetonitrile	3252-43-5	May 3, 2011
1,2-Dibromo-3-chloropropane (DBCP)	96-12-8	July 1, 1987
2,3-Dibromo-1-propanol	96-13-9	October 1, 1994
Dichloroacetic acid	79-43-6	May 1, 1996
<i>p</i> -Dichlorobenzene	106-46-7	January 1, 1989
3,3' -Dichlorobenzidine	91-94-1	October 1, 1987
3,3' -Dichlorobenzidine dihydrochloride	612-83-9	May 15, 1998
1,4-Dichloro-2-butene	764-41-0	January 1, 1990
3,3' -Dichloro-4,4' -diaminodiphenyl ether	28434-86-8	January 1, 1988
1,1-Dichloroethane	75-34-3	January 1, 1990
Dichloromethane (Methylene chloride)	75-09-2	April 1, 1988
1,2-Dichloropropane	78-87-5	January 1, 1990
1,3-Dichloro-2-propanol (1,3-DCP)	96-23-1	October 8, 2010
1,3-Dichloropropene	542-75-6	January 1, 1989
Diclofop-methyl	51338-27-3	April 6, 2010
Dieldrin	60-57-1	July 1, 1988
Dienestrol <u>Delisted January 4, 2013</u>	84-17-3	January 1, 1990
Diepoxybutane	1464-53-5	January 1, 1988
Diesel engine exhaust	—	October 1, 1990
Diethanolamine	111-42-2	June 22, 2012
Di(2-ethylhexyl)phthalate	117-81-7	January 1, 1988
1,2-Diethylhydrazine	1615-80-1	January 1, 1988
Diethyl sulfate	64-67-5	January 1, 1988
Diethylstilbestrol (DES)	56-53-1	February 27, 1987
Diglycidyl resorcinol ether (DGRE)	101-90-6	July 1, 1989
Dihydrosafrole	94-58-6	January 1, 1988
Diisononyl phthalate (DINP)	—	December 20, 2013
Diisopropyl sulfate	2973-10-6	April 1, 1993
3,3' -Dimethoxybenzidine (ortho-Dianisidine)	119-90-4	January 1, 1988
3,3' -Dimethoxybenzidine dihydrochloride (ortho-Dianisidine dihydrochloride)	20325-40-0	October 1, 1990
3,3' -Dimethoxybenzidine-based dyes metabolized to 3,3' -dimethoxybenzidine	—	June 11, 2004
3,3' -Dimethylbenzidine-based dyes metabolized to 3,3' -dimethylbenzidine	—	June 11, 2004
Dimethyl sulfate	77-78-1	January 1, 1988
4-Dimethylaminoazobenzene	60-11-7	January 1, 1988

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

<u>Chemical</u>	<u>CASNumber</u>	<u>Date</u>
trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole	55738-54-0	January 1, 1988
7,12-Dimethylbenz(a)anthracene	57-97-6	January 1, 1990
3,3'-Dimethylbenzidine (ortho-Tolidine)	119-93-7	January 1, 1988
3,3'-Dimethylbenzidine dihydrochloride	612-82-8	April 1, 1992
Dimethylcarbamoyl chloride	79-44-7	January 1, 1988
1,1-Dimethylhydrazine (UDMH)	57-14-7	October 1, 1989
1,2-Dimethylhydrazine	540-73-8	January 1, 1988
2,6-Dimethyl-N-nitrosomorpholine (DMNM)	1456-28-6	February 8, 2013
N,N-Dimethyl-p-toluidine	99-97-8	May 2, 2014
Dimethylvinylchloride	513-37-1	July 1, 1989
3,7-Dinitrofluoranthene	105735-71-5	August 26, 1997
3,9-Dinitrofluoranthene	22506-53-2	August 26, 1997
1,3-Dinitropyrene	75321-20-9	November 2, 2012
1,6-Dinitropyrene	42397-64-8	October 1, 1990
1,8-Dinitropyrene	42397-65-9	October 1, 1990
Dinitrotoluene mixture, 2,4-/2,6-	—	May 1, 1996
2,4-Dinitrotoluene	121-14-2	July 1, 1988
2,6-Dinitrotoluene	606-20-2	July 1, 1995
Di-n-propyl isocinchomeronate (MGK Repellent 326)	136-45-8	May 1, 1996
1,4-Dioxane	123-91-1	January 1, 1988
Diphenylhydantoin (Phenytoin)	57-41-0	January 1, 1988
Diphenylhydantoin (Phenytoin), sodium salt	630-93-3	January 1, 1988
Direct Black 38 (technical grade)	1937-37-7	January 1, 1988
Direct Blue 6 (technical grade)	2602-46-2	January 1, 1988
Direct Brown 95 (technical grade)	16071-86-6	October 1, 1988
Disperse Blue 1	2475-45-8	October 1, 1990
Diuron	330-54-1	May 31, 2002
Doxorubicin hydrochloride (Adriamycin)	25316-40-9	July 1, 1987
Emissions from combustion of coal	—	August 7, 2013
Emissions from high-temperature unrefined rapeseed oil	—	January 3, 2014
Epichlorohydrin	106-89-8	October 1, 1987
Epoxiconazole	135319-73-2	April 15, 2011
Erionite	12510-42-8/ 66733-21-9	October 1, 1988
Estradiol 17B	50-28-2	January 1, 1988
Estragole	140-67-0	October 29, 1999
Estrogens, steroidal	—	August 19, 2005
Estrogen-progestogen (combined) used as menopausal therapy	—	November 4, 2011
Estrone	53-16-7	January 1, 1988
Estropipate	7280-37-7	August 26, 1997
Ethanol in alcoholic beverages	—	April 29, 2011
Ethinylestradiol	57-63-6	January 1, 1988
Ethoprop	13194-48-4	February 27, 2001
Ethyl acrylate	140-88-5	July 1, 1989
Ethylbenzene	100-41-4	June 11, 2004
Ethyl methanesulfonate	62-50-0	January 1, 1988
Ethyl-4,4'-dichlorobenzilate	510-15-6	January 1, 1990
Ethylene dibromide	106-93-4	July 1, 1987
Ethylene dichloride (1,2-Dichloroethane)	107-06-2	October 1, 1987
Ethylene oxide	75-21-8	July 1, 1987
Ethylene thiourea	96-45-7	January 1, 1988
Ethyleneimine (Aziridine)	151-56-4	January 1, 1988

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

<i>Chemical</i>	<i>CASNumber</i>	<i>Date</i>
Etoposide	33419-42-0	November 4, 2011
Etoposide in combination with cisplatin and bleomycin	—	November 4, 2011
Fenoxycarb	72490-01-8	June 2, 2000
Folpet	133-07-3	January 1, 1989
Formaldehyde (gas)	50-00-0	January 1, 1988
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole	3570-75-0	January 1, 1988
FumonisinB ₁	116355-83-0	November 14, 2003
Furan	110-00-9	October 1, 1993
Furazolidone	67-45-8	January 1, 1990
Furmecyclox	60568-05-0	January 1, 1990
Fusarin C	79748-81-5	July 1, 1995
Gallium arsenide	1303-00-0	August 1, 2008
Ganciclovir	82410-32-0	August 26, 1997
Gasoline engine exhaust (condensates/extracts)	—	October 1, 1990
Gemfibrozil	25812-30-0	December 22, 2000
Glass wool fibers (inhalable and biopersistent)	—	July 1, 1990
Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole)	67730-11-4	January 1, 1990
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole)	67730-10-3	January 1, 1990
Glycidaldehyde	765-34-4	January 1, 1988
Glycidol	556-52-5	July 1, 1990
Griseofulvin	126-07-8	January 1, 1990
Gyromitrin (Acetaldehyde methylformylhydrazone)	16568-02-8	January 1, 1988
HC Blue 1	2784-94-3	July 1, 1989
Heptachlor	76-44-8	July 1, 1988
Heptachlor epoxide	1024-57-3	July 1, 1988
Herbal remedies containing plant species of the genus Aristolochia	—	July 9, 2004
Hexachlorobenzene	118-74-1	October 1, 1987
Hexachlorobutadiene	87-68-3	May 3, 2011
Hexachlorocyclohexane (technical grade)	—	October 1, 1987
Hexachlorodibenzodioxin	34465-46-8	April 1, 1988
Hexachloroethane	67-72-1	July 1, 1990
2,4-Hexadienal (89% trans, trans isomer; 11% cis, trans isomer)	—	March 4, 2005
Hexamethylphosphoramide	680-31-9	January 1, 1988
Hydrazine	302-01-2	January 1, 1988
Hydrazine sulfate	10034-93-2	January 1, 1988
Hydrazobenzene (1,2-Diphenylhydrazine)	122-66-7	January 1, 1988
1-Hydroxyanthraquinone	129-43-1	May 27, 2005
Imazalil	35554-44-0	May 20, 2011
Indeno [1,2,3-cd]pyrene	193-39-5	January 1, 1988
Indium phosphide	22398-80-7	February 27, 2001
IQ (2-Amino-3-methylimidazo[4,5-f]quinoline)	76180-96-6	April 1, 1990
Iprodione	36734-19-7	May 1, 1996
Iprovalicarb	140923-17-7	June 1, 2007
	140923-25-7	
Iron dextran complex	9004-66-4	January 1, 1988
Isobutyl nitrite	542-56-3	May 1, 1996
Isoprene	78-79-5	May 1, 1996
Isopyrazam	881686-58-1	July 24, 2012
Isosafrole <u>Delisted December 8, 2006</u>	120-58-1	October 1, 1989
Isoxaflutole	141112-29-0	December 22, 2000
Kresoxim-methyl	143390-89-0	February 3, 2012

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

<i>Chemical</i>	<i>CAS Number</i>	<i>Date</i>
Lactofen	77501-63-4	January 1, 1989
Lasiocarpine	303-34-4	April 1, 1988
Lead acetate	301-04-2	January 1, 1988
Lead and lead compounds	—	October 1, 1992
Lead phosphate	7446-27-7	April 1, 1988
Lead subacetate	1335-32-6	October 1, 1989
Leather dust	—	April 29, 2011
Lindane and other hexachlorocyclohexane isomers	—	October 1, 1989
Lynestrenol	52-76-6	February 27, 2001
Malonaldehyde, sodium salt	24382-04-5	May 3, 2011
Mancozeb	8018-01-7	January 1, 1990
Maneb	12427-38-2	January 1, 1990
Marijuana smoke	—	June 19, 2009
Me-A-alpha-C(2-Amino-3-methyl-9H-pyrido[2,3-b]indole)	68006-83-7	January 1, 1990
Medroxyprogesterone acetate	71-58-9	January 1, 1990
Megestrol acetate	595-33-5	March 28, 2014
MeIQ(2-Amino-3,4-dimethylimidazo[4,5-f]quinoline)	77094-11-2	October 1, 1994
MeIQx(2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline)	77500-04-0	October 1, 1994
Melphalan	148-82-3	February 27, 1987
Mepanipyryn	110235-47-7	July 1, 2008
Merphalan	531-76-0	April 1, 1988
Mestranol	72-33-3	April 1, 1988
Metam potassium	137-41-7	December 31, 2010
Metham sodium	137-42-8	November 6, 1998
8-Methoxypsoralen with ultraviolet A therapy	298-81-7	February 27, 1987
5-Methoxypsoralen with ultraviolet A therapy	484-20-8	October 1, 1988
2-Methylaziridine (Propyleneimine)	75-55-8	January 1, 1988
Methylazoxymethanol	590-96-5	April 1, 1988
Methylazoxymethanol acetate	592-62-1	April 1, 1988
Methyl carbamate	598-55-0	May 15, 1998
3-Methylcholanthrene	56-49-5	January 1, 1990
5-Methylchrysene	3697-24-3	April 1, 1988
4,4'-Methylene bis(2-chloroaniline)	101-14-4	July 1, 1987
4,4'-Methylene bis(N,N-dimethyl)benzenamine	101-61-1	October 1, 1989
4,4'-Methylene bis(2-methylaniline)	838-88-0	April 1, 1988
4,4'-Methylenedianiline	101-77-9	January 1, 1988
4,4'-Methylenedianiline dihydrochloride	13552-44-8	January 1, 1988
Methyleugenol	93-15-2	November 16, 2001
Methylhydrazine and its salts	—	July 1, 1992
2-Methylimidazole	693-98-1	June 22, 2012
4-Methylimidazole	822-36-6	January 7, 2011
Methyl iodide	74-88-4	April 1, 1988
Methylmercury compounds	—	May 1, 1996
Methyl isobutyl ketone	108-10-1	November 4, 2011
Methyl methanesulfonate	66-27-3	April 1, 1988
2-Methyl-1-nitroanthraquinone (of uncertain purity)	129-15-7	April 1, 1988
N-Methyl-N'-nitro-N-nitrosoguanidine	70-25-7	April 1, 1988
N-Methylolacrylamide	924-42-5	July 1, 1990
alpha-Methyl styrene (alpha-Methylstyrene)	98-83-9	November 2, 2012
Methylthiouracil	56-04-2	October 1, 1989
Metiram	9006-42-2	January 1, 1990
Metronidazole	443-48-1	January 1, 1988
Michler's ketone	90-94-8	January 1, 1988

<i>Chemical</i>	<i>CAS Number</i>	<i>Date</i>
Mirex	2385-85-5	January 1, 1988
Mitomycin C	50-07-7	April 1, 1988
MON 4660 (dichloroacetyl-1-oxa-4-azaspiro(4,5)-decane)	71526-07-3	March 22, 2011
MON 13900 (furalazole)	121776-33-8	March 22, 2011
3-Monochloropropane-1,2-diol (3-MCPD)	96-24-2	October 8, 2010
Monocrotaline	315-22-0	April 1, 1988
MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture)	113803-47-7	November 4, 2011
5-(Morpholinomethyl)-3-[(5-nitro-furfurylidene)-amino]-2-oxazolidinone	139-91-3	April 1, 1988
Mustard Gas	505-60-2	February 27, 1987
MX (3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone)	77439-76-0	December 22, 2000
Nafenopin	3771-19-5	April 1, 1988
Nalidixic acid	389-08-2	May 15, 1998
Naphthalene	91-20-3	April 19, 2002
1-Naphthylamine	134-32-7	October 1, 1989
2-Naphthylamine	91-59-8	February 27, 1987
Nickel (Metallic)	7440-02-0	October 1, 1989
Nickel acetate	373-02-4	October 1, 1989
Nickel carbonate	3333-67-3	October 1, 1989
Nickel carbonyl	13463-39-3	October 1, 1987
Nickel compounds	—	May 7, 2004
Nickel hydroxide	12054-48-7; 12125-56-3	October 1, 1989
Nickelocene	1271-28-9	October 1, 1989
Nickel oxide	1313-99-1	October 1, 1989
Nickel refinery dust from the pyrometallurgical process	—	October 1, 1987
Nickel subsulfide	12035-72-2	October 1, 1987
Niridazole	61-57-4	April 1, 1988
Nitrapyrin	1929-82-4	October 5, 2005
Nitrilotriacetic acid	139-13-9	January 1, 1988
Nitrilotriacetic acid, trisodium salt monohydrate	18662-53-8	April 1, 1989
5-Nitroacenaphthene	602-87-9	April 1, 1988
5-Nitro- <i>o</i> -anisidine <u>Delisted December 8, 2006</u>	99-59-2	October 1, 1989
<i>o</i> -Nitroanisole	91-23-6	October 1, 1992
Nitrobenzene	98-95-3	August 26, 1997
4-Nitrobiphenyl	92-93-3	April 1, 1988
6-Nitrochrysene	7496-02-8	October 1, 1990
Nitrofen (technical grade)	1836-75-5	January 1, 1988
2-Nitrofluorene	607-57-8	October 1, 1990
Nitrofurazone	59-87-0	January 1, 1990
1-[(5-Nitrofurfurylidene)-amino]-2-imidazolidinone	555-84-0	April 1, 1988
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide	531-82-8	April 1, 1988
Nitrogen mustard (Mechlorethamine)	51-75-2	January 1, 1988
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	55-86-7	April 1, 1988
Nitrogen mustard N-oxide	126-85-2	April 1, 1988
Nitrogen mustard N-oxide hydrochloride	302-70-5	April 1, 1988
Nitromethane	75-52-5	May 1, 1997
2-Nitropropane	79-46-9	January 1, 1988
1-Nitropyrene	5522-43-0	October 1, 1990
4-Nitropyrene	57835-92-4	October 1, 1990
N-Nitrosodi-n-butylamine	924-16-3	October 1, 1987
N-Nitrosodiethanolamine	1116-54-7	January 1, 1988

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

<i>Chemical</i>	<i>CAS Number</i>	<i>Date</i>
N-Nitrosodiethylamine	55-18-5	October 1, 1987
N-Nitrosodimethylamine	62-75-9	October 1, 1987
p-Nitrosodiphenylamine	156-10-5	January 1, 1988
N-Nitrosodiphenylamine	86-30-6	April 1, 1988
N-Nitrosodi-n-propylamine	621-64-7	January 1, 1988
N-Nitroso-N-ethylurea	759-73-9	October 1, 1987
3-(N-Nitrosomethylamino)propionitrile	60153-49-3	April 1, 1990
4-(N-Nitrosomethylamino)-1-(3-pyridyl)1-butanone	64091-91-4	April 1, 1990
N-Nitrosomethylethylamine	10595-95-6	October 1, 1989
N-Nitroso-N-methylurea	684-93-5	October 1, 1987
N-Nitroso-N-methylurethane	615-53-2	April 1, 1988
N-Nitrosomethylvinylamine	4549-40-0	January 1, 1988
N-Nitrosomorpholine	59-89-2	January 1, 1988
N-Nitrosornicotine	16543-55-8	January 1, 1988
N-Nitrosopiperidine	100-75-4	January 1, 1988
N-Nitrosopyrrolidine	930-55-2	October 1, 1987
N-Nitrososarcosine	13256-22-9	January 1, 1988
o-Nitrotoluene	88-72-2	May 15, 1998
Norethisterone (Norethindrone)	68-22-4	October 1, 1989
Norethynodrel	68-23-5	February 27, 2001
Ochratoxin A	303-47-9	July 1, 1990
Oil Orange SS	2646-17-5	April 1, 1988
Oral contraceptives, combined	—	October 1, 1989
Oral contraceptives, sequential	—	October 1, 1989
Oryzalin	19044-88-3	September 12, 2008
Oxadiazon	19666-30-9	July 1, 1991
Oxazepam	604-75-1	October 1, 1994
Oxymetholone	434-07-1	January 1, 1988
Oxythioquinox (Chinomethionat)	2439-01-2	August 20, 1999
Palygorskite fibers (> 5µm in length)	12174-11-7	December 28, 1999
Panfuran S	794-93-4	January 1, 1988
Pentachlorophenol	87-86-5	January 1, 1990
Pentosan polysulfate sodium	—	April 18, 2014
Phenacetin	62-44-2	October 1, 1989
Phenazopyridine	94-78-0	January 1, 1988
Phenazopyridine hydrochloride	136-40-3	January 1, 1988
Phenesterin	3546-10-9	July 1, 1989
Phenobarbital	50-06-6	January 1, 1990
Phenolphthalein	77-09-8	May 15, 1998
Phenoxybenzamine	59-96-1	April 1, 1988
Phenoxybenzamine hydrochloride	63-92-3	April 1, 1988
Phenoxybenzamine hydrochloride	63-92-3	April 1, 1988
o-Phenylenediamine and its salts	95-54-5	May 15, 1998
Phenyl glycidyl ether	122-60-1	October 1, 1990
Phenylhydrazine and its salts	—	July 1, 1992
o-Phenylphenate, sodium	132-27-4	January 1, 1990
o-Phenylphenol	90-43-7	August 4, 2000
PhiP(2-Amino-1-methyl-6-phenylimidazol[4,5-b]pyridine)	105650-23-5	October 1, 1994
Pioglitazone	111025-46-8	April 18, 2014
Polybrominated biphenyls	—	January 1, 1988
Polychlorinated biphenyls	—	October 1, 1989
Polychlorinated biphenyls (containing 60 or more percent chlorine by molecular weight)	—	January 1, 1988

<i>Chemical</i>	<i>CASNumber</i>	<i>Date</i>
Polychlorinated dibenzo-p-dioxins	—	October 1, 1992
Polychlorinated dibenzofurans	—	October 1, 1992
Polygeenan	53973-98-1	January 1, 1988
Ponceau MX	3761-53-3	April 1, 1988
Ponceau 3R	3564-09-8	April 1, 1988
Potassium bromate	7758-01-2	January 1, 1990
Primidone	125-33-7	August 20, 1999
Procarbazine	671-16-9	January 1, 1988
Procarbazine hydrochloride	366-70-1	January 1, 1988
Procymidone	32809-16-8	October 1, 1994
Progesterone	57-83-0	January 1, 1988
Pronamide	23950-58-5	May 1, 1996
Propachlor	1918-16-7	February 27, 2001
1,3-Propane sultone	1120-71-4	January 1, 1988
Propargite	2312-35-8	October 1, 1994
beta-Propiolactone	57-57-8	January 1, 1988
Propoxur	114-26-1	August 11, 2006
Propylene glycol mono- <i>t</i> -butyl ether	57018-52-7	June 11, 2004
Propylene oxide	75-56-9	October 1, 1988
Propylthiouracil	51-52-5	January 1, 1988
Pulegone	89-82-7	April 18, 2014
Pymetrozine	123312-89-0	March 22, 2011
Pyridine	110-86-1	May 17, 2002
Quinoline and its strong acid salts	—	October 24, 1997
Radionuclides	—	July 1, 1989
Reserpine	50-55-5	October 1, 1989
Residual (heavy) fuel oils	—	October 1, 1990
Resmethrin	10453-86-8	July 1, 2008
Riddelliine	23246-96-0	December 3, 2004
<u>Saccharin Delisted April 6, 2001</u>	81-07-2	October 1, 1989
<u>Saccharin, sodium Delisted January 17, 2003</u>	128-44-9	January 1, 1988
Safrole	94-59-7	January 1, 1988
Salted fish, Chinese-style	—	April 29, 2011
Selenium sulfide	7446-34-6	October 1, 1989
Shale-oils	68308-34-9	April 1, 1990
Silica, crystalline (airborne particles of respirable size)	—	October 1, 1988
Soots, tars, and mineral oils (untreated and mildly treated oils and used engine oils)	—	February 27, 1987
Spirodiclofen	148477-71-8	October 8, 2010
Spironolactone	52-01-7	May 1, 1997
Stanozolol	10418-03-8	May 1, 1997
Sterigmatocystin	10048-13-2	April 1, 1988
Streptozotocin (streptozocin)	18883-66-4	January 1, 1988
Strong inorganic acid mists containing sulfuric acid	—	March 14, 2003
Styrene oxide	96-09-3	October 1, 1988
Sulfallate	95-06-7	January 1, 1988
Sulfasalazine (Salicylazosulfapyridine)	599-79-1	May 15, 1998
Talc containing asbestiform fibers	—	April 1, 1990
Tamoxifen and its salts	10540-29-1	September 1, 1996
Terrazole	2593-15-9	October 1, 1994
Testosterone and its esters	58-22-0	April 1, 1988
3,3',4,4'-Tetrachloroazobenzene	14047-09-7	July 24, 2012
2,3,7,8-Tetrachlorodibenzo-para-dioxin (TCDD)	1746-01-6	January 1, 1988

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

<u>Chemical</u>	<u>CAS Number</u>	<u>Date</u>
1,1,1,2-Tetrachloroethane	630-20-6	September 13, 2013
1,1,2,2-Tetrachloroethane	79-34-5	July 1, 1990
Tetrachloroethylene (Perchloroethylene)	127-18-4	April 1, 1988
<i>p</i> -a,a,a-Tetrachlorotoluene	5216-25-1	January 1, 1990
Tetrafluoroethylene	116-14-3	May 1, 1997
Tetranitromethane	509-14-8	July 1, 1990
Thioacetamide	62-55-5	January 1, 1988
4,4'-Thiodianiline	139-65-1	April 1, 1988
Thiodicarb	59669-26-0	August 20, 1999
Thiouracil	141-90-2	June 11, 2004
Thiourea	62-56-6	January 1, 1988
Thorium dioxide	1314-20-1	February 27, 1987
Titanium dioxide (airborne, unbound particles of respirable size)	—	September 2, 2011
Tobacco, oral use of smokeless products	—	April 1, 1988
Tobacco smoke	—	April 1, 1988
Toluene diisocyanate	26471-62-5	October 1, 1989
ortho-Toluidine	95-53-4	January 1, 1988
ortho-Toluidine hydrochloride	636-21-5	January 1, 1988
<u>para-Toluidine Delisted October 29, 1999</u>	106-49-0	January 1, 1990
Toxaphene (Polychlorinated camphenes)	8001-35-2	January 1, 1988
Toxins derived from <i>Fusarium moniliforme</i> (<i>Fusarium verticillioides</i>)	—	August 7, 2009
Treosulfan	299-75-2	February 27, 1987
Triamterene	396-01-0	April 18, 2014
S,S,S-Tributyl phosphorotrithioate (Tribufos, DEF)	78-48-8	February 25, 2011
Trichlormethine (Trimustine hydrochloride)	817-09-4	January 1, 1992
Trichloroacetic acid	76-03-9	September 13, 2013
Trichloroethylene	79-01-6	April 1, 1988
2,4,6-Trichlorophenol	88-06-2	January 1, 1988
1,2,3-Trichloropropane	96-18-4	October 1, 1992
Trimethyl phosphate	512-56-1	May 1, 1996
2,4,5-Trimethylaniline and its strong acid salts	—	October 24, 1997
2,4,6-Trinitrotoluene (TNT)	118-96-7	December 19, 2008
Triphenyltin hydroxide	76-87-9	July 1, 1992
<u>Tris(aziridinyl)-para-benzoquinone (Triaziquone)</u> <u>Delisted December 8, 2006</u>	68-76-8	October 1, 1989
Tris(1-aziridinyl)phosphine sulfide (Thiotepa)	52-24-4	January 1, 1988
Tris(2-chloroethyl) phosphate	115-96-8	April 1, 1992
Tris(2,3-dibromopropyl)phosphate	126-72-7	January 1, 1988
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)	13674-87-8	October 28, 2011
Trp-P-1 (Tryptophan-P-1)	62450-06-0	April 1, 1988
Trp-P-2 (Tryptophan-P-2)	62450-07-1	April 1, 1988
Trypan blue (commercial grade)	72-57-1	October 1, 1989
Unleaded gasoline (wholly vaporized)	—	April 1, 1988
Uracil mustard	66-75-1	April 1, 1988
Urethane (Ethyl carbamate)	51-79-6	January 1, 1988
Vanadium pentoxide (orthorhombic crystalline form)	1314-62-1	February 11, 2005
Vinclozolin	50471-44-8	August 20, 1999
Vinyl bromide	593-60-2	October 1, 1988
Vinyl chloride	75-01-4	February 27, 1987
4-Vinylcyclohexene	100-40-3	May 1, 1996
4-Vinyl-1-cyclohexene diepoxide (Vinyl cyclohexene dioxide)	106-87-6	July 1, 1990

<u>Chemical</u>	<u>CAS Number</u>	<u>Date</u>
Vinyl fluoride	75-02-5	May 1, 1997
Vinyl trichloride (1,1,2-Trichloroethane)	79-00-5	October 1, 1990
Wood dust	—	December 18, 2009
2,6-Xylidine (2,6-Dimethylaniline)	87-62-7	January 1, 1991
Zalcitabine	7481-89-2	August 7, 2009
Zidovudine (AZT)	30516-87-1	December 18, 2009
Zileuton	111406-87-2	December 22, 2000
Zineb <u>Delisted October 29, 1999</u>	12122-67-7	January 1, 1990

CHEMICALS KNOWN TO THE STATE TO CAUSE REPRODUCTIVE TOXICITY

<u>Chemical</u>	<u>Type of Reproductive Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Acetazolamide	developmental	59-66-5	August 20, 1999
Acetohydroxamic acid	developmental	546-88-3	April 1, 1990
Acrylamide	developmental, male	79-06-1	February 25, 2011
Actinomycin D	developmental	50-76-0	October 1, 1992
All-trans retinoic acid	developmental	302-79-4	January 1, 1989
Alprazolam	developmental	28981-97-7	July 1, 1990
Altretamine	developmental, male	645-05-6	August 20, 1999
Amantadine hydrochloride	developmental	665-66-7	February 27, 2001
Amikacin sulfate	developmental	39831-55-5	July 1, 1990
Aminoglutethimide	developmental	125-84-8	July 1, 1990
tert-Amyl methyl ether <u>Delisted December 13, 2013</u>	developmental	994-05-8	December 18, 2009
Aminoglycosides	developmental	—	October 1, 1992
Aminopterin	developmental, female	54-62-6	July 1, 1987
Amiodarone hydrochloride	developmental, female, male	19774-82-4	August 26, 1997
Amitraz	developmental	33089-61-1	March 30, 1999
Amoxapine	developmental	14028-44-5	May 15, 1998
Anabolic steroids	female, male	—	April 1, 1990
Angiotensin converting enzyme (ACE) inhibitors	developmental	—	October 1, 1992
Anisindione	developmental	117-37-3	October 1, 1992
Arsenic (inorganic oxides)	developmental	—	May 1, 1997
Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.)	developmental, female	50-78-2	July 1, 1990
Atenolol	developmental	29122-68-7	August 26, 1997
Auranofin	developmental	34031-32-8	January 29, 1999
Avermectin B1 (Abamectin)	developmental	71751-41-2	December 3, 2010
Azathioprine	developmental	446-86-6	September 1, 1996
Barbiturates	developmental	—	October 1, 1992
Beclomethasone dipropionate	developmental	5534-09-8	May 15, 1998
Benomyl	developmental, male	17804-35-2	July 1, 1991
Benzene	developmental, male	71-43-2	December 26, 1997
Benzodiazepines	developmental	—	October 1, 1992
Benzphetamine hydrochloride	developmental	5411-22-3	April 1, 1990

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

<u>Chemical</u>	<u>Type of Reproductive Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Bischloroethyl nitrosourea (BCNU) (Carmustine)	developmental	154-93-8	July 1, 1990
Bisphenol A (BPA) <u>Delisted April 19, 2013</u>	developmental	80-05-7	April 11, 2013
Bromacil lithium salt	developmental	53404-19-6	May 18, 1999
1-Bromopropane	male		January 17, 2003
2-Bromopropane	developmental, female, male	106-94-5	December 7, 2004
Bromoxynil	female, male	75-26-3	May 31, 2005
Bromoxynil octanoate	developmental	1689-84-5	October 1, 1990
Butabarbital sodium	developmental	1689-99-2	May 18, 1999
1,3-Butadiene	developmental	143-81-7	October 1, 1992
1,4-Butanediol dimethane-sulfonate (Busulfan)	developmental, female, male	106-99-0	April 16, 2004
Butyl benzyl phthalate (BBP)	developmental	55-98-1	January 1, 1989
n-Butyl glycidyl ether <u>Delisted April 4, 2014</u>	male	85-68-7	December 2, 2005
		2426-08-6	August 7, 2009
Cadmium	developmental, male	—	May 1, 1997
Carbamazepine	developmental	298-46-4	January 29, 1999
Carbaryl	developmental, female, male	63-25-2	August 7, 2009
Carbon disulfide	developmental, female, male	75-15-0	July 1, 1989
Carbon monoxide	developmental	630-08-0	July 1, 1989
Carboplatin	developmental	41575-94-4	July 1, 1990
Chenodiol	developmental	474-25-9	April 1, 1990
Chlorambucil	developmental	305-03-3	January 1, 1989
Chlorcyclizine hydrochloride	developmental	1620-21-9	July 1, 1987
Chlordecone (Kepone)	developmental	143-50-0	January 1, 1989
Chlordiazepoxide	developmental	58-25-3	January 1, 1992
Chlordiazepoxide hydrochloride	developmental	438-41-5	January 1, 1992
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	developmental	13010-47-4	July 1, 1990
Chloroform	developmental	67-66-3	August 7, 2009
2-Chloropropionic acid	male	598-78-7	August 7, 2009
Chlorsulfuron <u>Delisted June 6, 2014</u>	developmental, female, male	64902-72-3	May 14, 1999
Chromium (hexavalent compounds)	developmental, female, male	—	December 19, 2008
Cidofovir	developmental, female, male	113852-37-2	January 29, 1999
Cladribine	developmental	4291-63-8	September 1, 1996
Clarithromycin	developmental	81103-11-9	May 1, 1997
Clobetasol propionate	developmental, female	25122-46-7	May 15, 1998
Clomiphene citrate	developmental	50-41-9	April 1, 1990
Clorazepate dipotassium	developmental	57109-90-7	October 1, 1992
Cocaine	developmental, female	50-36-2	July 1, 1989
Codeine phosphate	developmental	52-28-8	May 15, 1998
Colchicine	developmental, male	64-86-8	October 1, 1992
Conjugated estrogens	developmental	—	April 1, 1990
Cyanazine	developmental	21725-46-2	April 1, 1990
Cycloate	developmental	1134-23-2	March 19, 1999
Cyclohexanol <u>Delisted January 25, 2002</u>	male	108-93-0	November 6, 1998
Cycloheximide	developmental	66-81-9	January 1, 1989

<u>Chemical</u>	<u>Type of Reproductive Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Cyclophosphamide (anhydrous)	developmental, female, male	50-18-0	January 1, 1989
Cyclophosphamide (hydrated)	developmental, female, male	6055-19-2	January 1, 1989
Cyhexatin	developmental	13121-70-5	January 1, 1989
Cytarabine	developmental	147-94-4	January 1, 1989
Dacarbazine	developmental	4342-03-4	January 29, 1989
Danazol	developmental	17230-88-5	April 1, 1990
Daunorubicin hydrochloride	developmental	23541-50-6	July 1, 1990
2,4-D butyric acid	developmental, male	94-82-6	June 18, 1999
o,p' -DDT	developmental, female, male	789-02-6	May 15, 1998
p,p' -DDT	developmental, female, male	50-29-3	May 15, 1998
2,4 DP (dichloroprop)	developmental	120-36-5	April 27, 1999
<u>Delisted January 25, 2002</u>			
Demeclocycline hydrochloride (internal use)	developmental	64-73-3	January 1, 1992
Diazepam	developmental	439-14-5	January 1, 1992
Diazoxide	developmental	364-98-7	February 27, 2001
1,2-Dibromo-3-chloropropane (DBCP)	male	96-12-8	February 27, 1987
Di-n-butyl phthalate (DBP)	developmental, female, male	84-74-2	December 2, 2005
Dichloroacetic acid	developmental, male	79-43-6	August 7, 2009
1,1-Dichloro-2,2-bis(p-chlorophenyl) ethylene (DDE)	developmental, male	72-55-9	March 30, 2010
Dichlorophene	developmental	97-23-4	April 27, 1999
Dichlorophenamide	developmental	120-97-8	February 27, 2001
Diclofop methyl	developmental	51338-27-3	March 5, 1999
Dicumarol	developmental	66-76-2	October 1, 1992
Di(2-ethylhexyl)phthalate (DEHP)	developmental, male	117-81-7	October 24, 2003
Diethylstilbestrol (DES)	developmental	56-53-1	July 1, 1987
Diffunisal	developmental, female	22494-42-4	January 29, 1999
Diglycidylether	male	2238-07-5	August 7, 2009
<u>Delisted April 4, 2014</u>			
Di-n-hexyl phthalate (DnHP)	female, male	84-75-3	December 2, 2005
Dihydroergotamine mesylate	developmental	6190-39-2	May 1, 1997
Di-isodecyl phthalate (DIDP)	developmental	68515-49-1/ 26761-40-0	April 20, 2007
Diltiazem hydrochloride	developmental	33286-22-5	February 27, 2001
N,N-Dimethylacetamide	developmental, male	127-19-5	May 21, 2010
m-Dinitrobenzene	male	99-65-0	July 1, 1990
o-Dinitrobenzene	male	528-29-0	July 1, 1990
p-Dinitrobenzene	male	100-25-4	July 1, 1990
2,4-Dinitrotoluene	male	121-14-2	August 20, 1999
2,6-Dinitrotoluene	male	606-20-2	August 20, 1999
Dinitrotoluene (technical grade)	female, male	—	August 20, 1999
Dinocap	developmental	39300-45-3	April 1, 1990
Dinoseb	developmental, male	88-85-7	January 1, 1989
Diphenylhydantoin (Phenytoin)	developmental	57-41-0	July 1, 1987
Disodium cyanodithioimidocarbonate	developmental	138-93-2	March 30, 1999
Doxorubicin hydrochloride (Adriamycin)	developmental, male	25316-40-9	January 29, 1999
Doxycycline (internal use)	developmental	564-25-0	July 1, 1990
Doxycycline calcium (internal use)	developmental	94088-85-4	January 1, 1992
Doxycycline hyclate (internal use)	developmental	24390-14-5	October 1, 1991

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

<u>Chemical</u>	<u>Type of Reproductive Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Doxycycline monohydrate (internal use)	developmental	17086-28-1	October 1, 1991
Endrin	developmental	72-20-8	May 15, 1998
Environmental tobacco smoke (ETS)	developmental	—	June 9, 2006
Epichlorohydrin	male	106-89-8	September 1, 1996
Ergotamine tartrate	developmental	379-79-3	April 1, 1990
Estropipate	developmental	7280-37-7	August 26, 1997
Ethionamide	developmental	536-33-4	August 26, 1997
Ethyl alcohol in alcoholic beverages	developmental	—	October 1, 1987
Ethyl-tert-butyl ether	male	637-92-3	December 18, 2009
<u>Delisted December 13, 2013</u>			
Ethyl dipropylthiocarbamate	developmental	759-94-4	April 27, 1999
Ethylene dibromide	developmental, male	106-93-4	May 15, 1998
Ethylene glycol monoethyl ether	developmental, male	110-80-5	January 1, 1989
Ethylene glycol monomethyl ether	developmental, male	109-86-4	January 1, 1989
Ethylene glycol monoethyl ether acetate	developmental, male	111-15-9	January 1, 1993
Ethylene glycol monomethyl ether acetate	developmental, male	110-49-6	January 1, 1993
Ethylene oxide	female	75-21-8	February 27, 1987
	developmental, male		August 7, 2009
Ethylene thiourea	developmental	96-45-7	January 1, 1993
2-Ethylhexanoic acid	developmental	149-57-5	August 7, 2009
<u>Delisted December 13, 2013</u>			
Etodolac	developmental, female	41340-25-4	August 20, 1999
Etoposide	developmental	33419-42-0	July 1, 1990
Etretinate	developmental	54350-48-0	July 1, 1987
Fenoxaprop ethyl	developmental	66441-23-4	March 26, 1999
Filgrastim	developmental	121181-53-1	February 27, 2001
Fluazifop butyl	developmental	69806-50-4	November 6, 1998
Flunisolide	developmental, female	3385-03-3	May 15, 1998
Fluorouracil	developmental	51-21-8	January 1, 1989
Fluoxymesterone	developmental	76-43-7	April 1, 1998
Flurazepam hydrochloride	developmental	1172-18-5	October 1, 1992
Flurbiprofen	developmental, female	5104-49-4	August 20, 1999
Flutamide	developmental	13311-84-7	July 1, 1990
Fluticasone propionate	developmental	80474-14-2	May 15, 1998
Fluvalinate	developmental	69409-94-5	November 6, 1998
Ganciclovir	developmental, male	82410-32-0	August 26, 1997
Ganciclovir sodium	developmental, male	107910-75-8	August 26, 1997
Gemfibrozil	female, male	25812-30-0	August 20, 1999
Goserelin acetate	developmental, female, male	65807-02-5	August 26, 1997
Halazepam	developmental	23092-17-3	July 1, 1990
Halobetasol propionate	developmental	66852-54-8	August 20, 1999
Haloperidol	developmental, female	52-86-8	January 29, 1999
Halothane	developmental	151-67-7	September 1, 1996
Heptachlor	developmental	76-44-8	August 20, 1999
Hexachlorobenzene	developmental	118-74-1	January 1, 1989
Hexafluoroacetone	<u>developmental</u> , male	684-16-2	August 1, 2008
Hexamethylphosphoramide	male	680-31-9	October 1, 1994
Histrelin acetate	developmental	—	May 15, 1998

<u>Chemical</u>	<u>Type of Reproductive Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Hydramethylnon	developmental, male	67485-29-4	March 5, 1999
Hydrogen cyanide (HCN) and cyanide salts (CN salts)	male		July 5, 2013
Hydroxyurea	developmental	127-07-1	May 1, 1997
Idarubicin hydrochloride	developmental, male	57852-57-0	August 20, 1999
Ifosfamide	developmental	3778-73-2	July 1, 1990
Iodine-131	developmental	10043-66-0	January 1, 1989
Isotretinoin	developmental	4759-48-2	July 1, 1987
Lead	developmental, female, male	—	February 27, 1987
Leuprolide acetate	developmental, female, male	74381-53-6	August 26, 1997
Levodopa	developmental	59-92-7	January 29, 1999
Levonorgestrel implants	female	797-63-7	May 15, 1998
Linuron	developmental	330-55-2	March 19, 1999
Lithium carbonate	developmental	554-13-2	January 1, 1991
Lithium citrate	developmental	919-16-4	January 1, 1991
Lorazepam	developmental	846-49-1	July 1, 1990
Lovastatin	developmental	75330-75-5	October 1, 1992
Mebendazole	developmental	31431-39-7	August 20, 1999
Medroxyprogesterone acetate	developmental	71-58-9	April 1, 1990
Megestrol acetate	developmental	595-33-5	January 1, 1991
Melphalan	developmental	148-82-3	July 1, 1990
Menotropins	developmental	9002-68-0	April 1, 1990
Meprobamate	developmental	57-53-4	January 1, 1992
Mercaptopurine	developmental	6112-76-1	July 1, 1990
Mercury and mercury compounds	developmental	—	July 1, 1990
Methacycline hydrochloride	developmental	3963-95-9	January 1, 1991
Metham sodium	developmental	137-42-8	May 15, 1998
Methanol	developmental	67-56-1	March 16, 2012
Methazole	developmental	20354-26-1	December 1, 1999
Methimazole	developmental	60-56-0	July 1, 1990
Methotrexate	developmental	59-05-2	January 1, 1989
Methotrexate sodium	developmental	15475-56-6	April 1, 1990
Methyl bromide as a structural fumigant	developmental	74-83-9	January 1, 1993
Methyl chloride	developmental	74-87-3	March 10, 2000
Methyl n-butyl ketone	male	591-78-6	August 7, 2009
Methyl isobutyl ketone (MIBK)	developmental	108-10-1	March 28, 2014
Methyl isocyanate (MIC)	developmental, female	624-83-9	November 12, 2010
Methyl isopropyl ketone <u>Delisted April 4, 2014</u>	developmental	563-80-4	February 17, 2012
Methyl mercury	developmental	—	July 1, 1987
N-Methylpyrrolidone	developmental	872-50-4	June 15, 2001
α -Methylstyrene <u>Delisted April 4, 2014</u>	female	98-83-9	July 29, 2011
Methyltestosterone	developmental	58-18-4	April 1, 1990
Metiram	developmental	9006-42-2	March 30, 1999
Midazolam hydrochloride	developmental	59467-96-8	July 1, 1990
Minocycline hydrochloride (internal use)	developmental	13614-98-7	January 1, 1992
Misoprostol	developmental	59122-46-2	April 1, 1990
Mitoxantrone hydrochloride	developmental	70476-82-3	July 1, 1990

<u>Chemical</u>	<u>Type of Reproductive Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Molinate	developmental, female, male	2212-67-1	December 11, 2009
Myclobutanil	developmental, male	88671-89-0	April 16, 1999
Nabam	developmental	142-59-6	March 30, 1999
Nafarelin acetate	developmental	86220-42-0	April 1, 1990
Neomycin sulfate (internal use)	developmental	1405-10-3	October 1, 1992
Netilmicin sulfate	developmental	56391-57-2	July 1, 1990
Nickel carbonyl	developmental	13463-39-3	September 1, 1996
Nicotine	developmental	54-11-5	April 1, 1990
Nifedipine	developmental, female, male	21829-25-4	January 29, 1999
Nimodipine	developmental	66085-59-4	April 24, 2001
Nitrapyrin	developmental	1929-82-4	March 30, 1999
Nitrobenzene	male	98-95-3	March 30, 2010
Nitrofurantoin	male	67-20-9	April 1, 1991
Nitrogen mustard (Mechlorethamine)	developmental	51-75-2	January 1, 1989
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	developmental	55-86-7	July 1, 1990
Nitrous oxide	developmental, female	10024-97-2	August 1, 2008
Norethisterone (Norethindrone)	developmental	68-22-4	April 1, 1990
Megestrol Norethisterone acetate (Norethindrone acetate)	developmental	51-98-9	October 1, 1991
Norethisterone (Norethindrone) /Ethinyl estradiol	developmental	68-22-4/ 57-63-6	April 1, 1990
Norethisterone (Norethindrone)/Mestranol	developmental	68-22-4/ 72-33-3	April 1, 1990
Norgestrel	developmental	6533-00-2	April 1, 1990
Oxadiazon	developmental	19666-30-9	May 15, 1998
Oxazepam	developmental	604-75-1	October 1, 1992
p,p'-Oxybis(benzenesulfonylhydrazide) <u>Delisted December 13, 2013</u>	developmental	80-51-3	August 7, 2009
Oxydemeton methyl	female, male	301-12-2	November 6, 1998
Oxymetholone	developmental	434-07-1	May 1, 1997
Oxytetracycline (internal use)	developmental	79-57-2	January 1, 1991
Oxytetracycline hydrochloride (internal use)	developmental	2058-46-0	October 1, 1991
Oxythioquinox (Chinomethionat)	developmental	2439-01-2	November 6, 1998
Paclitaxel	developmental, female, male	33069-62-4	August 26, 1997
Paramethadione	developmental	115-67-3	July 1, 1990
Penicillamine	developmental	52-67-5	January 1, 1991
Pentobarbital sodium	developmental	57-33-0	July 1, 1990
Pentostatin	developmental	53910-25-1	September 1, 1996
Phenacemide	developmental	63-98-9	July 1, 1990
Phenprocoumon	developmental	435-97-2	October 1, 1992
Phenylglycidyl ether <u>Delisted April 4, 2014</u>	male	122-60-1	August 7, 2009
Phenylphosphine	developmental male	638-21-1	August 7, 2009
Pimozide	developmental, female	2062-78-4	August 20, 1999
Pipobroman	developmental	54-91-1	July 1, 1990
Plicamycin	developmental	18378-89-7	April 1, 1990
Polybrominated biphenyls	developmental	—	October 1, 1994

<u>Chemical</u>	<u>Type of Reproductive Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Polychlorinated biphenyls	developmental	—	January 1, 1991
Potassium dimethyldithiocarbamate	developmental	128-03-0	March 30, 1999
Pravastatin sodium	developmental	81131-70-6	March 3, 2000
Prednisolone sodium phosphate	developmental	125-02-0	August 20, 1999
Procarbazine hydrochloride	developmental	366-70-1	July 1, 1990
Propargite	developmental	2312-35-8	June 15, 1999
Propylthiouracil	developmental	51-52-5	July 1, 1990
Pyrimethamine	developmental	58-14-0	January 29, 1999
Quazepam	developmental	36735-22-5	August 26, 1997
Quizalofop-ethyl	male	76578-14-8	December 24, 1999
Resmethrin	developmental	10453-86-8	November 6, 1998
Retinol/retinyl esters, when in daily dosages in excess of 10,000 IU, or 3,000 retinol equivalents. (NOTE: Retinol/retinyl esters are required and essential for maintenance of normal reproductive function. The recommended daily level during pregnancy is 8,000 IU.)	developmental	—	July 1, 1989
Ribavirin	developmental male	36791-04-5 36791-04-5	April 1, 1990 February 27, 2001
Rifampin	developmental, female	13292-46-1	February 27, 2001
Secobarbital sodium	developmental	309-43-3	October 1, 1992
Sermorelin acetate	developmental	—	August 20, 1999
Sodium dimethyldithiocarbamate	developmental	128-04-1	March 30 1999
Sodium fluoroacetate	male	62-74-8	November 6, 1998
Streptomycin sulfate	developmental	3810-74-0	January 1, 1991
Streptozocin (streptozotocin)	developmental, female, male	18883-66-4	August 20, 1999
Sulfasalazine (Salicylazosulfapyridine)	male	599-79-1	January 29, 1999
Sulfur dioxide	developmental	7446-09-5	July 29, 2011
Sulindac	developmental, female	38194-50-2	January 29, 1999
Tamoxifen citrate	developmental	54965-24-1	July 1, 1990
Temazepam	developmental	846-50-4	April 1, 1990
Teniposide	developmental	29767-20-2	September 1, 1996
Terbacil	developmental	5902-51-2	May 18, 1999
Testosterone cypionate	developmental	58-20-8	October 1, 1991
Testosterone enanthate	developmental	315-37-7	April 1, 1990
2,3,7,8-Tetrachlorodibenzo-para-dioxin (TCDD)	developmental	1746-01-6	April 1, 1991
Tetracycline (internal use)	developmental	60-54-8	October 1, 1991
Tetracyclines (internal use)	developmental	—	October 1, 1992
Tetracycline hydrochloride (internal use)	developmental	64-75-5	January 1, 1991
Thalidomide	developmental	50-35-1	July 1, 1987
Thioguanine	developmental	154-42-7	July 1, 1990
Thiophanate methyl	female, male	23564-05-8	May 18, 1999
Tobacco smoke (primary)	developmental, female, male	—	April 1, 1988
Tobramycin sulfate	developmental	49842-07-1	July 1, 1990
Toluene	developmental female	108-88-3	January 1, 1991 August 7, 2009
Triadimefon	developmental, female, male	43121-43-3	March 30, 1999
Triazolam	developmental	28911-01-5	April 1, 1990

<u>Chemical</u>	<u>Type of Reproductive Toxicity</u>	<u>CAS No.</u>	<u>Date Listed</u>
Tributyltin methacrylate	developmental	2155-70-6	December 1, 1999
Trichloroethylene	developmental, male	79-01-6	January 31, 2014
Trientine hydrochloride	developmental	38260-01-4	February 27, 2001
Triforine	developmental	26644-46-2	June 18, 1999
1,3,5-Triglycidyl-s-triazinetriene <u>Delisted December 13, 2013</u>	male	2451-62-9	August 7, 2009
Trilostane	developmental	13647-35-3	April 1, 1990
Trimethadione	developmental	127-48-0	January 1, 1991
Trimetrexate glucuronate	developmental	82952-64-5	August 26, 1997
Triphenyltin hydroxide	developmental	76-87-9	March 18, 2002
Uracil mustard	developmental, female, male	66-75-1	January 1, 199
Urethane	developmental	51-79-6	October 1, 1994
Urofollitropin	developmental	97048-13-0	April 1, 1990
Valproate (Valproic acid)	developmental	99-66-1	July 1, 1987
Vinblastine sulfate	developmental	143-67-9	July 1, 1990
Vinclozolin	developmental	50471-44-8	May 15, 1998
Vincristine sulfate	developmental	2068-78-2	July 1, 1990
4-Vinylcyclohexene	female, male	100-40-03	August 7, 2009
Vinyl cyclohexene dioxide (4-Vinyl-1-cyclohexene diepoxide)	female, male	106-87-6	August 1, 2008
Warfarin	developmental	81-81-2	July 1, 1987
Zileuton	developmental, female	111406-87-2	December 22, 2000

Date: June 6, 2014

**OFFICE OF ENVIRONMENTAL
HEALTH HAZARD ASSESSMENT**

**SAFE DRINKING WATER AND TOXIC
ENFORCEMENT ACT OF 1986
(PROPOSITION 65)**

**NOTICE TO CHANGE THE BASIS FOR
LISTING FOR HEXAFLUOROACETONE AND
PHENYLPHOSPHINE AS KNOWN TO THE
STATE OF CALIFORNIA TO CAUSE
REPRODUCTIVE TOXICITY**

JUNE 6, 2014

Effective June 6, 2014, the basis for the listing of hexafluoroacetone and phenylphosphine under Proposition 65¹ as known to cause reproductive toxicity is the state’s qualified experts mechanism. These two chemicals were originally added to the Proposition 65 list as causing reproductive toxicity via the “Labor Code

¹ The Safe Drinking Water and Toxic Enforcement Act of 1986, commonly known as Proposition 65, is codified in Health and Safety Code section 25249.5 *et seq.*

mechanism” pursuant to Labor Code section 6382(d), which is incorporated by reference in Health and Safety Code section 25249.8(a). Based on changes to certain federal regulations that affected the basis for the original listings of these chemicals as causing reproductive toxicity, the California Environmental Protection Agency’s Office of Environmental Health Hazard Assessment (OEHHA) referred the chemicals to the Developmental and Reproductive Toxicant Identification Committee (DARTIC) for reconsideration. In its official capacity as the “state’s qualified experts” at a public meeting held on May 21, 2014, the DARTIC determined that the two chemicals have been clearly shown, through scientifically valid testing according to generally accepted principles, to cause reproductive toxicity and should remain on the Proposition 65 list. Regulations governing the listing of chemicals by the DARTIC are set out in Title 27, California Code of Regulations, section 25305(b)(1).

The effective dates of listing as known to cause reproductive toxicity remain unchanged: August 1, 2008 for hexafluoroacetone and August 7, 2009 for phenylphosphine.

In summary, the chemicals in the table below are being retained on the Proposition 65 list as known to the State to cause reproductive toxicity.

Chemical	CAS No.	Toxicological Endpoints	Listing Mechanism¹
Hexa-fluoro-acetone	684-16-2	Developmental ² Male reproductive	SQE
Phenyl-phosphine	638-21-1	Male reproductive ³	SQE

¹SQE: State's Qualified Experts

²The DARTIC added the general endpoint of developmental toxicity, effective June 6, 2014, to the listing.

³The general endpoint of male reproductive toxicity identified by the DARTIC was also the endpoint that supported the original listing. Due to a typographical error, the Proposition 65 list had incorrectly stated the general endpoint as developmental toxicity.

**SUSPENSION OF
ACTION REGARDING
UNDERGROUND REGULATIONS**

(Pursuant to Title 1, section 280, of the California Code of Regulations)

On April 4, 2014, the Office of Administrative Law (OAL) received a petition challenging Department Operations Manual (DOM) section 42020.6, issued by the Department of Corrections and Rehabilitation (CDCR) as an alleged underground regulation. The rule is titled "Inmate Access to Computing."

On May 16, 2014, CDCR certified to OAL that CDCR will no longer issue, use, enforce or attempt to enforce the challenged rule contained in DOM section 42020.6, which restricts CDCR inmates who have "computer expertise" from accessing institution computers. Therefore, pursuant to California Code of Regulations, title 1, section 280, OAL must suspend all action on this petition.

**DEPARTMENT OF CORRECTIONS
AND REHABILITATION**

May 16, 2014

Debra Cornez, Director
Office of Administrative Law
300 Capitol Mall, Suite 1250
Sacramento, Ca 95814

Dear Ms. Cornez:

This letter is in response to a petition received by your office on April 4, 2014, authored by Stefan Hudson. The petition, dated April 1, 2014, challenges the Department Operations Manual (DOM) policy under Section 42020.6, Inmate Access to Computing. The petitioner requests a review of the language which restricts inmates who have "computer expertise" from accessing institution computers.

CDCR has reviewed the petition and relevant documents. As a result, CDCR will no longer issue, use, enforce, or attempt to enforce the language contained in the DOM Section 42020.6, which restricts CDCR inmates who have "computer expertise" from accessing institution computers. Our intent is to revise and amend the DOM article that contains Section 42020.6.

I make this certification in accordance with Section 280 of Title 1, CCR. A copy of this certification has been sent to Mr. Hudson as required by Section 280 (a) of Title 1, CCR.

If you have any questions or concerns, please contact Michael Morrison, Special Assistant to the Undersecretary at (916) 323-6001, or Timothy Lockwood, Chief, Regulation and Policy Management Branch (RPMB) at (916) 445-2212.

Sincerely,

/s/

DIANA TOCHE
Undersecretary (A), Administration & Offender Services
California Department of Corrections and Rehabilitation

Enclosures

cc: Jeffrey A. Beard, PhD, Secretary, California Department of Corrections and Rehabilitation
Timothy Lockwood, Chief, Regulation and Policy Management Branch

On May 20, 2014, the Regulation and Policy Management Branch staff mailed a copy of the attached California Department of Corrections and Rehabilitation's petition response to the Office of Administrative Law. This response is regarding a petition dated April 1, 2014, and a true copy thereof, is enclosed in a sealed envelope to petitioner Stefan Hudson at the following address:

Stefan Hudson
V-88029
Avenal State Prison
P. O. Box 900
Avenal, CA 93204-0900

I declare, under penalty of perjury, that the foregoing is true and correct.

/s/
Signature of Declarant
Date: May 20, 2014

TIMOTHY M. LOCKWOOD, Chief
Regulation & Policy Management Branch

**SUMMARY OF REGULATORY
ACTIONS**

**REGULATIONS FILED WITH
SECRETARY OF STATE**

This Summary of Regulatory Actions lists regulations filed with the Secretary of State on the dates indicated. Copies of the regulations may be obtained by contacting the agency or from the Secretary of State, Archives, 1020 O Street, Sacramento, CA 95814, (916) 653-7715. Please have the agency name and the date filed (see below) when making a request.

File# 2014-0425-02
BUREAU OF AUTOMOTIVE REPAIR
Smog Check Inspector and Repair Technician Application

This action without regulatory effect amends the Smog Check Inspector and Repair Technician Application.

Title 16
California Code of Regulations
AMEND: 3340.29
Filed 05/21/2014
Agency Contact: Vincent Somma (916) 403-8560

File# 2014-0512-01
CALIFORNIA HEALTH BENEFIT EXCHANGE
2015 Standard Benefit Design

The California Patient Protection and Affordable Care Act established the California Health Benefit Exchange (HBEX). HBEX is responsible for arranging and contracting with health insurance issuers to provide affordable, quality health insurance coverage to qualified individuals and qualified employers through the Exchange. In this emergency rulemaking action, HBEX adopts the 2015 Standard Benefit Plan Designs, which standardize the way health plans are designed. The 2015 Standard Benefit Plan Designs are incorpo-

rated by reference in section 6460 of title 10 of the California Code of Regulations.

Title 10
California Code of Regulations
ADOPT: 6460
Filed 05/21/2014
Effective 05/21/2014
Agency Contact: Brandon Ross (916) 228-8281

File# 2014-0410-02
DEPARTMENT OF FISH AND WILDLIFE
Hunter Education Instructor Incentives

The Department of Fish and Wildlife amended section 360 of title 14 of the California Code of Regulations to add a subdivision (e) to establish Hunter Education Instructor Incentive Tags.

Title 14
California Code of Regulations
AMEND: 360
Filed 05/21/2014
Effective 07/01/2014
Agency Contact: Roy Griffith (916) 358-2946

File# 2014-0415-02
DEPARTMENT OF HEALTH CARE SERVICES
Long-Term Care Reimbursement

The Department of Health Care Services submitted this timely certificate of compliance to make permanent the emergency regulations adopted in OAL file no. 2013-1216-04E. There are no changes to the emergency regulations previously approved. The emergency action amended sections of Title 22 of the California Code of Regulations to adjust reimbursement rates established by the Department as required by Welfare and Institutions Code section 14105.

Title 22
California Code of Regulations
AMEND: 51510, 51510.1, 51510.2, 51510.3, 51511, 51511.5, 51511.6, 51535, 51535.1, 54501
Filed 05/22/2014
Effective 05/22/2014
Agency Contact: Ben Carranco (916) 440-7766

File# 2014-0415-01
DEPARTMENT OF PUBLIC HEALTH
Hexavalent Chromium MCL

In this regulatory action, the Department is adopting a drinking water maximum contamination levels (MCL) for hexavalent chromium and amending existing drinking water notification regulations to be consistent with statutory requirements.

Title 22
 California Code of Regulations
 AMEND: 64213, 64431, 64432, 64447.2, 64463,
 64465, 64481, 64530, 64534, 64534.2, 64534.8,
 64535.2, 64535.4, 64671.80
 Filed 05/28/2014
 Effective 07/01/2014
 Agency Contact: Dawn Basciano (916) 440-7367

File# 2014-0506-02
 FISH AND GAME COMMISSION
 Harvesting of Kelp and Other Aquatic Plants
 This action without regulatory effect updates the Har-
 vesting of Kelp and Other Aquatic Plants form for 2014.

Title 14
 California Code of Regulations
 AMEND: 165
 Filed 05/22/2014
 Agency Contact: Sherrie Fonbuena (916) 654-9866

File# 2014-0410-01
 STATE WATER RESOURCES CONTROL BOARD
 Lower Santa Maria R. and Tributaries to Oso Flaco
 Lake Nutrient TMDLs
 This action by the State Water Resources Control
 Board (State Board) amends the Water Quality Control
 Plan for the Central Coastal Basin (Basin Plan) by
 adopting total maximum daily loads for nitrogen com-
 pounds and orthophosphate in the Lower Santa Maria
 River Watershed and tributaries to Oso Flaco Lake.
 This basin plan amendment was adopted by the Region-
 al Water Quality Control Board, Central Coast Region
 (Regional Board), pursuant to Resolution
 R3-2013-0013 on May 30, 2013, and approved by the
 State Board on February 4, 2014 pursuant to Resolution
 2014-0009.

Title 23
 California Code of Regulations
 ADOPT: 3929.12
 Filed 05/22/2014
 Effective 05/22/2014
 Agency Contact: Larry Harlan (805) 594-6195

**CCR CHANGES FILED
 WITH THE SECRETARY OF STATE
 WITHIN December 25, 2013 TO
 May 28, 2014**

All regulatory actions filed by OAL during this peri-
 od are listed below by California Code of Regulations
 titles, then by date filed with the Secretary of State, with
 the Manual of Policies and Procedures changes adopted

by the Department of Social Services listed last. For fur-
 ther information on a particular file, contact the person
 listed in the Summary of Regulatory Actions section of
 the Notice Register published on the first Friday more
 than nine days after the date filed.

Title 2
 05/19/14 ADOPT: 1181.1, 1181.2, 1181.3, 1181.4,
 1181.5, 1181.6, 1181.7, 1181.8, 1181.9,
 1181.10, 1181.11, 1181.12, 1181.13,
 1182.1, 1182.2, 1182.3, 1182.4, 1182.5,
 1182.6, 1182.7, 1182.8, 1182.9, 1182.10,
 1182.11, 1182.12, 1182.13, 1182.14,
 1182.15, 1182.16, 1183.1, 1183.2,
 1183.3, 1183.4, 1183.5, 1183.6, 1183.7,
 1183.8, 1183.9, 1183.10, 1183.11,
 1183.12, 1183.13, 1183.14, 1183.15,
 1183.16, 1183.17, 1183.18, 1184.1,
 1185.1, 1185.2, 1185.3, 1185.4, 1185.5,
 1185.6, 1185.7, 1185.8, 1185.9, 1186.1,
 1186.2, 1186.3, 1186.4, 1186.5, 1186.6,
 1186.7, 1187.1, 1187.2, 1187.3, 1187.4,
 1187.5, 1187.6, 1187.7, 1187.8, 1187.9,
 1187.10, 1187.11, 1187.12, 1187.13,
 1187.14, 1187.15, 1188.1, 1188.2,
 1190.1, 1190.2, 1190.3, 1190.4, 1190.5
 REPEAL: 1181, 1181.1, 1181.2, 1181.4,
 1182, 1182.1, 1182.2, 1182.3, 1182.4,
 1182.5, 1183, 1183.01, 1183.02, 1183.03,
 1183.04, 1183.05, 1183.06, 1183.07,
 1183.08, 1183.081, 1183.09, 1183.1,
 1183.11, 1183.12, 1183.13, 1183.131,
 1183.14, 1183.2, 1183.21, 1183.25,
 1183.30, 1183.31, 1183.32, 1184.5,
 1184.6, 1184.7, 1184.8, 1184.9, 1184.10,
 1184.11, 1185, 1185.1, 1185.2, 1185.21,
 1185.3, 1185.4, 1185.5, 1185.6, 1185.7,
 1186, 1186.5, 1186.51, 1186.52, 1186.53,
 1186.54, 1186.55, 1186.6, 1186.61,
 1186.62, 1186.63, 1186.64, 1186.65,
 1186.7, 1186.71, 1186.72, 1186.73, 1187,
 1187.2, 1187.3, 1187.4, 1187.5, 1187.6,
 1187.7, 1187.8, 1187.9, 1188, 1188.1,
 1188.2, 1188.3, 1188.31, 1188.4, 1189,
 1189.1, 1189.2, 1189.3, 1189.6, 1189.61,
 1190, 1190.01, 1190.02, 1190.03,
 1190.04, 1190.05
 05/01/14 ADOPT: 18706.1 AMEND: 18706
 05/01/14 AMEND: 18950.1
 05/01/14 AMEND: 18705.2 REPEAL: 18704.2
 04/30/14 AMEND: 18704
 04/30/14 AMEND: 18707.9
 04/16/14 ADOPT: 599.760.1 AMEND: 599.757,
 599.759, 599.761, 599.768, 599.769

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

REPEAL: 599.755, 599.760, 599.764,
599.765, 599.766, 599.767
03/10/14 AMEND: 1900, 2002, 2003
03/05/14 ADOPT: 630, 632.5, 632.11 AMEND:
631, 631.5, 632, 632.6, 632.7, 632.8,
632.9, 632.10 REPEAL: 632.5, 632.11
02/10/14 AMEND: 58000
01/27/14 AMEND: 56800
01/21/14 AMEND: 1194
01/13/14 AMEND: 55300

Title 3

05/14/14 ADOPT: 1280, 1280.1, 1280.8, 1280.10
AMEND: 1280.7
05/12/14 AMEND: 3591.20(a)
04/24/14 AMEND: 3435(b)
04/04/14 AMEND: 3435(b)
03/19/14 AMEND: 3406(b)
03/18/14 ADOPT: 6471 AMEND: 6000, 6400
03/18/14 AMEND: 3423(b)
03/10/14 AMEND: 3589(a)
03/05/14 ADOPT: 1358.3
02/26/14 AMEND: 3434(b)(c)(d)
02/25/14 AMEND: 3417(b)
02/25/14 AMEND: 3700(b)
02/20/14 AMEND: 3423(b)
02/20/14 AMEND: 3701, 3701.1, 3701.2, 3701.3,
3701.4, 3701.5, 3701.6, 3701.7, 3701.8
02/12/14 AMEND: 3700(c)
02/10/14 AMEND: 3435(b)
02/05/14 AMEND: 3435(b)
01/27/14 AMEND: 3406(b)
01/23/14 AMEND: 3591.11
01/14/14 ADOPT: 1392.13
01/09/14 AMEND: 1300, 1300.1, 1300.3,
1300.11, 1300.12, 1300.13, 1300.14,
1300.15 REPEAL: 1300.2, 1300.4

Title 4

05/19/14 AMEND: 7030, 7032, 7033, 7034, 7035,
7036, 7037, 7040, 7042
05/15/14 ADOPT: 7113, 7114, 7115, 7116, 7117,
7118, 7119, 7120, 7121, 7122, 7123,
7124, 7125, 7126, 7127, 7128, 7129
05/12/14 AMEND: 1632
04/07/14 AMEND: 1656, 1658
04/03/14 AMEND: 10030, 10031, 10032, 10033,
10034, 10035, 10036
04/02/14 AMEND: 2066
03/28/14 AMEND: 10302, 10305, 10315, 10317, 10
320, 10322, 10325, 10326, 10327, 10328,
10337
03/24/14 ADOPT: 10170.1, 10170.2, 10170.3,
10170.4, 10170.5, 10170.6, 10170.7,
10170.8, 10170.9, 10170.10, 10170.11,
10170.12, 10170.13, 10170.14, 10170.15

03/11/14 ADOPT: 1927.1
03/10/14 ADOPT: 10080, 10081, 10082, 10083,
10084, 10085, 10086, 10087
02/03/14 ADOPT: 10170.16, 10170.17, 10170.18,
10170.19, 10170.20, 10170.21,
10170.22, 10170.23, 10170.24
01/21/14 ADOPT: 10170.1, 10170.2, 10170.3,
10170.4, 10170.5, 10170.6, 10170.7,
10170.8, 10170.9, 10170.10, 10170.11,
10170.12, 10170.13, 10170.14, 10170.15
12/26/13 ADOPT: 8034(d)

Title 5

05/19/14 AMEND: 80035.5
05/05/14 ADOPT: 14037, 14038, 14039, 14040,
14041, 14042
05/05/14 ADOPT: 3051.19, 3051.20, 3051.21,
3051.22, 3051.23, 3051.24 AMEND:
3001, 3023, 3025, 3029, 3030, 3031,
3040, 3043, 3051, 3051.1, 3051.2,
3051.3,.4, 3051.5, 3051.6, 3051.7,
3051.75, 3051.8, 3051.9, 3051.10,
3051.11, 3051.12, 3051.13, 3051.14,
3051.15, 3051.16, 3051.17, 3051.18,
3060, 3061, 3064, 3065, 3068, 3083,
3084, 3088 REPEAL: 3054
04/15/14 AMEND: 70020
04/01/14 AMEND: 80303
04/01/14 ADOPT: 15498, 15498.1, 15498.2,
15498.3
02/28/14 ADOPT: 19843, 19844, 19848, 19849,
19855 AMEND: 19815, 19816, 19816.1,
19817.2, 19819, 19820, 19824, 19828.4,
19840, 19845.2, 19850, 19851, 19852,
19853 REPEAL: 19839
02/13/14 ADOPT: 80033
02/06/14 ADOPT: 15494, 15495, 15496, 15497
02/05/14 ADOPT: 80691, 80692
02/03/14 AMEND: 850, 851, 852, 853, 853.5, 855,
857, 858, 859, 861, 862, 862.5, 863, 864
REPEAL: 854, 864.5, 865, 866, 867,
867.5, 868
01/23/14 AMEND: 22000

Title 7

02/27/14 AMEND: 213

Title 8

05/14/14 ADOPT: 344.76, 344.77
05/05/14 AMEND: 1529, 1532, 1532.1, 1532.2,
1535, 3204, 5150, 5157, 5161, 5189,
5190, 5191, 5192, 5194, 5197, 5198,
5200, 5201, 5202, 5206, 5207, 5208,
5208.1, 5209, 5210, 5211, 5212, 5213,
5214, 5215, 5217, 5218, 5219, 5220,
8358, 8359

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

05/05/14	ADOPT: 1929 AMEND: 1504, 1930, 1931, 1932, 1934, 1935, 1936, 5154, 5191, 5194, 5415, 5417, 5449, 5451, 5531, 5532, 5533, 5534, 5535, 5537, 5538, 5541, 5542, 5543, 5545, 5546, 5547, 5549, 5555, 5556, 5558, 5560, 5566, 5568, 5569, 5570, 5573, 5574, 5575, 5576, 5577, 5578, 5579, 5580, 5583, 5585.1, 5589, 5590, 5592, 5593, 5594, 5595, 5596, 5597, 5598, 5599, 5601, 5602, 5606, 5607, 5608, 5616, 5617, 5618, 5619, 5620, 5621, 5622, 5624	05/12/14	ADOPT: 6650, 6652, 6654, 6656, 6657, 6658, 6660, 6662, 6664, 6666, 6668, 6670
04/28/14	AMEND: 2940.2, 2940.7, 8602, 8610, 8611, 8615	05/07/14	AMEND: 2498.4.9
04/16/14	AMEND: 10205.14 REPEAL: 9788.01, 9788.1, 9788.11, 9788.2, 9788.3, 9788.31, 9788.32, 9788.4, 9788.45, 9788.5, 9788.6, 9788.7, 9788.8, 9788.9, 9788.91	04/29/14	AMEND: 2509.1, 2509.3, 2509.4, 2509.5, 2509.6, 2509.7, 2509.8, 2509.9, 2509.10, 2509.11, 2509.12, 2509.13, 2509.14, 2509.15, 2509.16, 2509.17, 2509.18, 2509.19, 2509.20
04/14/14	AMEND: 3650	04/28/14	AMEND: 2498.6
04/14/14	AMEND: 5001	04/23/14	AMEND: 3541, 3568
04/09/14	AMEND: 1619.1(b)	04/23/14	AMEND: 2498.5
04/03/14	AMEND: 4355	04/21/14	ADOPT: 2907.1, 2907.2, 2907.3, 2907.4
04/01/14	AMEND: 1520, 3384	04/10/14	ADOPT: 2562.1, 2562.2, 2562.3, 2562.4
02/12/14	ADOPT: 9785.5, 9792.6.1, 9792.9.1, 9792.10.1, 9792.10.2, 9792.10.3, 9792.10.4, 9792.10.5, 9792.10.6, 9792.10.7, 9792.10.8, 9792.10.9 AMEND: 9785, 9792.6, 9792.7, 9792.9, 9792.10, 9792.11, 9792.12, 9792.15	04/01/14	ADOPT: 6700, 6702, 6704, 6706, 6708, 6710, 6712, 6714, 6716, 6718
02/12/14	ADOPT: 9792.5.4, 9792.5.5, 9792.5.6, 9792.5.7, 9792.5.8, 9792.5.9, 9792.5.10, 9792.5.11, 9792.5.12, 9792.5.13, 9792.5.14, 9792.5.15 AMEND: 9792.5.1, 9792.5.3, 9793, 9794, 9795	04/01/14	ADOPT: 6408, 6410, 6450, 6452, 6454, 6470, 6472, 6474, 6476, 6478, 6480, 6482, 6484, 6486, 6490, 6492, 6494, 6496, 6498, 6500, 6502, 6504, 6506, 6508, 6510, 6600, 6602, 6604, 6606, 6608, 6610, 6612, 6614, 6616, 6618, 6620
02/12/14	AMEND: 9780, 9780.1, 9783, 9783.1, 9785	04/01/14	ADOPT: 6800, 6802, 6804, 6806
02/05/14	AMEND: 10133.32, 10133.33, 10133.35, 10133.36	04/01/14	ADOPT: 6520, 6522, 6524, 6526, 6528, 6530, 6532, 6534, 6536, 6538
01/21/14	AMEND: 334	03/25/14	ADOPT: 6456
01/21/14	AMEND: 344, 344.1	03/17/14	ADOPT: 6458
01/09/14	AMEND: 8495, 8496, 8497, 8500	03/10/14	ADOPT: 6424, 6440
01/09/14	AMEND: 5155	03/06/14	ADOPT: 6420, 6422
01/07/14	AMEND: 4297	02/25/14	ADOPT: 2218.30
12/26/13	AMEND: 9789.12.2, 9789.12.3, 9789.12.4, 9789.12.8, 9789.19	02/24/14	ADOPT: 2594, 2594.1, 2594.2, 2594.3, 2594.4, 2594.5, 2594.6, 2594.7
Title 9		02/20/14	ADOPT: 8000, 8010, 8020, 8030, 8040, 8050, 8060, 8070
01/28/14	ADOPT: 7005.5 AMEND: 7005 REPEAL: 7144, 7145, 7146, 7147	02/11/14	AMEND: 3500, 3523, 3525, 3527, 3528, 3529, 3530, 3541, 3542, 3543, 3561, 3563, 3565, 3568, 3569, 3570, 3571, 3575, 3576, 3577, 3581, 3582, 3601, 3602, 3603, 3621, 3661, 3662, 3663, 3664, 3665, 3666, 3668, 3681, 3702, 3704, 3721, 3723, 3724, 3725, 3726, 3728, 3729, 3730, 3732, 3741, 3761
01/14/14	AMEND: 7214.1, 7220.7, 7227.2	02/10/14	ADOPT: 6650, 6652, 6654, 6656, 6657, 6658, 6660, 6662, 6664, 6666, 6668, 6670
Title 10		01/28/14	AMEND: 2318.6, 2353.1
05/21/14	ADOPT: 6460	01/28/14	AMEND: 2318.6, 2353.1, 2354
		01/24/14	ADOPT: 217, 217.5, 217.10, 217.15, 217.20, 217.25, 217.30, 217.35, 217.40, 217.45 AMEND: 202, 216, 218, 219, 221 REPEAL: 217

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

01/07/14 ADOPT: 1430 AMEND: 260.210,
260.211, 260.211.1, 260.231, 1422,
1422.7, 1423, 1581, 1582, 1805.204,
1950.122.8
12/30/13 AMEND: 260.237
12/27/13 AMEND: 2699.100, 2699.200,
2699.201, 2699.205, 2699.207,
2699.209, 2699.210, 2699.400
REPEAL: 2699.202, 2699.208, 2699.211

Title 11

05/20/14 AMEND: 1082
02/27/14 AMEND: 20
02/19/14 AMEND: 999.10
01/14/14 AMEND: 1015(c)
12/26/13 ADOPT: 4200, 4210, 4220, 4230, 4240

Title 13

05/19/14 ADOPT: 227.00, 227.02, 227.04, 227.06,
227.08, 227.10, 227.12, 227.14, 227.16,
227.18, 227.20, 227.22, 227.24, 227.26,
227.28, 227.30, 227.32, 227.34, 227.36,
227.38, 227.42, 227.44, 227.46, 227.48,
227.50, 227.52
05/01/14 AMEND: 125.02
03/13/14 AMEND: 1239
02/24/14 AMEND: 1
02/24/14 AMEND: 553.70
12/30/13 AMEND: 423.00

Title 14

05/22/14 AMEND: 165
05/21/14 AMEND: 360
05/19/14 AMEND: 149, 149.1
04/30/14 AMEND: 27.80
04/11/14 AMEND: 3550.15
04/07/14 AMEND: 790, 820.01
04/01/14 AMEND: 27.80
03/26/14 AMEND: 916.9(g)(2)(A),
936.9(g)(2)(A), 956.9(g)(2)(A)
03/25/14 ADOPT: 5200, 5201, 5202, 5203, 5204,
5205, 5206, 5207, 5208, 5209, 5210,
5211, 5300, 5301, 5302, 5303, 5304,
5305, 5306, 5307
03/24/14 AMEND: 228(a)
03/18/14 AMEND: 601, 702(a)(1)
02/19/14 AMEND: 7.00, 7.50, 8.00
02/10/14 AMEND: 701
02/06/14 AMEND: 1665.6(b)
01/21/14 AMEND: 7.50
01/16/14 ADOPT: 3100, 3101, 3102, 3103, 3104,
3105, 3106, 3107, 3108, 3109, 3110,
3111, 3112, 3113, 3114, 3115, 3116, 3117
01/14/14 AMEND: 165, 165.5
01/13/14 ADOPT: 4000

01/13/14 ADOPT: 2830, 2831, 2831.1, 2831.2,
2831.3, 2831.4, 2831.5, 2832, 2833,
2834, 2835 AMEND: 2000, 2085, 2501
12/26/13 AMEND: 228(a)
12/30/13 ADOPT: 1761, 1780, 1781, 1782, 1783,
1783.1, 1783.2, 1783.3, 1783.4, 1788

Title 15

05/14/14 AMEND: 3000, 3040, 3040.1, 3041,
3041.3, 3043, 3043.5, 3043.6, 3044,
3046, 3074.3, 3075.1, 3077.1, 3078.4,
3170.1, 3190, 3375.2, 3375.4, 3375.5,
3375.6, 3376, 3379, 3383
05/12/14 AMEND: 3043
04/21/14 REPEAL: 3999.12
03/28/14 ADOPT: 3999.17
03/24/14 AMEND: 3044, 3190, 3282, 3335
03/18/14 AMEND: 3290, 3315
02/11/14 ADOPT: 3999.15
02/11/14 ADOPT: 3999.16
02/06/14 ADOPT: 3750, 3751, 3752, 3753, 3754,
3756, 3760, 3761, 3761.1, 3762, 3763,
3764, 3765, 3766 AMEND: 3000,
3075.2, 3768.2, 3768.3
01/23/14 AMEND: 3000, 3075
01/15/14 REPEAL: 3999.9
01/09/14 ADOPT: 1712.2, 1714.2, 1730.2, 1740.2
AMEND: 1700, 1706, 1712, 1712.1,
1714, 1714.1, 1730, 1730.1, 1731, 1747,
1747.1, 1747.5, 1748, 1748.5, 1749,
1749.1, 1750, 1750.1, 1751, 1752, 1753,
1754, 1756, 1760, 1766, 1767, 1768,
1770, 1772, 1776, 1778, 1788, 1790,
1792
01/08/14 AMEND: 3044, 3190, 3315
01/08/14 AMEND: 3000, 3006, 3084.7, 3165,
3176, 3177, 3294.5, 3310, 3315, 3352,
3376, 3376.1, 3377.1, 3379, 3426, 3430,
3434

Title 16

05/21/14 AMEND: 3340.29
05/19/14 AMEND: 1023.16, 1023.17
05/05/14 AMEND: 120
04/24/14 AMEND: 1495.1, 1495.2
04/23/14 AMEND: 940
04/22/14 AMEND: 1419(c)
04/21/14 AMEND: 1508.1
04/14/14 AMEND: 1749
02/24/14 ADOPT: 1762 AMEND: 1745, 1769
02/19/14 AMEND: 1021
01/17/14 AMEND: 475, 476, 3065
01/16/14 ADOPT: 1138
01/13/14 AMEND: 70

01/07/14	AMEND: 1524	5570, 5573, 5574 REPEAL: 5450, 5512, 5563
01/07/14	ADOPT: 1018.01 AMEND: 1018	
12/31/13	ADOPT: 4172	02/20/14 ADOPT: 19266
Title 17		01/08/14 AMEND: 25106.5-1
05/20/14	ADOPT: 6550, 6551, 6553, 6553.1, 6555, 6557, 6557.1, 6557.2, 6557.3	Title 20
05/05/14	AMEND: 6050, 6051, 6070	04/22/14 AMEND: 1601, 1602, 1602.1, 1603, 1604, 1605, 1605.1, 1605.2, 1605.3, 1606, 1607, 1608
04/16/14	AMEND: 1230, 2641.57	01/28/14 AMEND: 2401, 2402
04/16/14	AMEND: 54342	01/08/14 AMEND: 1660, 1661, 1662, 1663, 1664, 1665
04/10/14	AMEND: 60201, 60203, 60205, 60207, 60210	01/08/14 AMEND: 1.2, 1.5, 1.9, 1.10, 1.13, 2.4, 3.3, 3.6, 4.2, 8.3, 13.1, 13.8, 13.11, 13.13, 14.1, 14.2, 14.5, 14.6, 15.2, 16.6, 18.1
03/12/14	ADOPT: 56068, 56069, 56070, 56071, 56072, 56073, 56074, 56620, 56621, 56622, 56623, 56624, 56625 AMEND: 56101	Title 21
01/28/14	ADOPT: 54521, 54522, 54523, 54524, 54525, 54526, 54527, 54528, 54529, 54530, 54531, 54532, 54533, 54534, 54535 AMEND: 54500, 54505, 54520 REPEAL: 54521, 54522, 54523, 54524, 54525	01/07/14 ADOPT: 2653, 2654, 2655, 2656, 2657, 2658
01/27/14	AMEND: 100600, 100601, 100602, 100608	Title 22
12/31/13	ADOPT: 95124 AMEND: 95101, 95102, 95103, 95104, 95105, 95110, 95111, 95112, 95113, 95114, 95115, 95116, 95117, 95118, 95119, 95120, 95121, 95122, 95123, 95129, 95130, 95131, 95132, 95133, 95150, 95151, 95152, 95153, 95154, 95155, 95156, 95157	05/28/14 AMEND: 64213, 64431, 64432, 64447.2, 64463, 64465, 64481, 64530, 64534, 64534.2, 64535.8, 64535.4, 64671.80
Title 18		05/22/14 AMEND: 51510, 51510.1, 51510.2, 51510.3, 51511, 51511.5, 51511.6, 51535, 51535.1, 54501
05/15/14	AMEND: 1603	04/07/14 REPEAL: 75040, 75041, 75042, 75043, 75044
05/14/14	ADOPT: 17942	04/03/14 AMEND: 97212, 97215, 97225, 97226, 97227, 97228, 97229, 97244, 97248, 97258, 97259, 97260, 97261
05/13/14	AMEND: 1699	03/25/14 AMEND: 97225, 97226, 97227
04/09/14	REPEAL: 18641, 19513	03/17/14 AMEND: 51516.1
04/02/14	AMEND: 1705	02/26/14 AMEND: 53800, 53810 REPEAL: 53830
03/10/14	ADOPT: 18662-0, 19002 AMEND: 18662-1, 18662-2, 18662-3, 18662-4, 18662-5, 18662-6, 18662-8 REPEAL: 18662-7, 18662-11, 18662-12, 18662-13, 18662-14	02/13/14 AMEND: 51003
03/04/14	AMEND: 1502	Title 23
02/25/14	ADOPT: 5255, 5256, 5453, 5552 AMEND: 5200, 5212, 5215, 5215.4, 5215.6, 5216, 5217, 5218, 5219, 5220, 5222, 5224, 5225, 5230, 5233, 5235, 5237, 5240, 5241, 5242, 5247, 5250, 5262, 5264, 5266, 5267, 5270, 5311, 5322, 5323.6, 5323.8, 5324, 5325.6, 5332, 5332.6, 5333, 5333.4, 5333.6, 5334, 5334.4, 5334.6, 5335, 5336.5, 5345, 5421, 5435, 5444, 5450, 5451, 5452, 5460, 5463, 5510, 5511, 5512, 5522.8, 5523.6, 5551, 5561, 5562, 5563,	05/22/14 ADOPT: 3929.12
		05/19/14 ADOPT: 3949.9
		05/07/14 ADOPT: 3929.10
		03/11/14 ADOPT: 3969.4
		02/27/14 AMEND: 2922
		02/04/14 AMEND: 2921
		01/09/14 ADOPT: 13.2, 21, 22, 23, 24, 25, 27, 29 AMEND: 13, 13.1, 13.2 (renumbered to 13.3), 20, 21 (renumbered to 26), 26 (renumbered to 28), 28 (renumbered to 30) REPEAL: 23, 24, 25, 27
		Title 25
		04/07/14 AMEND: 4353, 4369
		03/24/14 ADOPT: 6932 REPEAL: 6932
		Title 27
		05/13/14 AMEND: 27000
		04/30/14 AMEND: 10013, 10014
		04/16/14 AMEND: 25302, 25304

CALIFORNIA REGULATORY NOTICE REGISTER 2014, VOLUME NO. 23-Z

02/20/14	AMEND: 27001	04/14/14	ADOPT: 1300.67.005
Title 28		Title MPP	
05/07/14	AMEND: 1300.43.3, 1300.65, 1300.71, 1300.80.10	04/23/14	AMEND: 40-105, 42-422, 82-504
04/28/14	ADOPT: 1300.67.241	04/23/14	AMEND: 40-105, 42-422, 82-504

